Page 1 Extracted Terms:
- Circulation (journal)  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- ACC/AHA/ACCP/HRS Guideline  
- Clinical Practice Guidelines  
- Diagnosis and Management of Atrial Fibrillation  
- Atrial fibrillation  
- Heart Rhythm Society  
- American College of Clinical Pharmacy  
- American Heart Association  
- American College of Cardiology  
- Clinical data standards  
- Heart rhythm (as a clinical context)

Page 2 Extracted Terms:
**Key terms related to heart disease**

- Acute coronary syndrome  
- Alcohol (tobacco‑related risk factor)  
- Anticoagulants  
- Anticoagulation agents  
- Antiplatelet agents  
- Apixaban  
- Atrial fibrillation  
- Atrial flutter  
- Cardioversion (electrical)  
- Catheter ablation  
- Coronary artery disease  
- Coronary heart disease  
- Dabigatran  
- Edoxaban  
- Exercise (physical activity)  
- Heart failure  
- Hypertension  
- Idarucizumab (dabigatran reversal agent)  
- Left atrial appendage occlusion (LAAO)  
- Myocardial infarction (MI)  
- Obesity  
- Percutaneous coronary intervention (PCI)  
- Pulmonary vein isolation (PVI)  
- Risk factors (general)  
- Rivaroxaban  
- Sleep apnea  
- Stents (PCI stents)  
- Stroke (cardioembolic)  
- Surgical ablation (e.g., maze procedure)  
- Thromboembolism (mechanism and prevention)  
- Warfarin  
- Diabetes (as a cardiovascular risk‑modifier)  
- Weight loss/obesity management  
- Physical fitness  
- Smoking cessation  
- Alcohol consumption (moderation)  
- Caffeine consumption  
- Diet and dietary supplementation  
- Sleep hygiene (sleep quality)  
- Comprehensive cardiovascular care  

*(These terms capture the core concepts, therapies, risk factors, and procedural strategies related to heart disease as presented in the guideline.)*

Page 3 Extracted Terms:
**Key Terms Related to Heart Disease**

- Atrial Fibrillation (AF)
- Atrial Flutter (AFL)
- Thromboembolism  
- Anticoagulation  
- Active Bleeding on Anticoagulant  
- Reversal Drugs  
- Intracerebral Hemorrhage (ICH)  
- Periprocedural Management  
- Acute Coronary Syndrome (ACS)  
- Percutaneous Coronary Intervention (PCI)  
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Peripheral Artery Disease (PAD)  
- Heart Failure (HF)  
- Valvular Heart Disease (VHD)  
- Hypertrophic Cardiomyopathy (HCM)  
- Congenital Heart Disease / Adult Congenital Heart Disease (ACHD)  
- Atrioventricular Nodal Ablation (AVNA)  
- Catheter Ablation (AF)  
- Surgical Ablation (AF)  
- Pacemakers  
- Implantable Cardioverter–Defibrillators (ICDs)  
- Electrical Cardioversion  
- Pharmacological Cardioversion  
- Antiarrhythmic Drugs (maintenance of sinus rhythm)  
- Rate Control  
- Rhythm Control  
- Upstream Therapy  
- WPW (Wolff–Parkinson–White) Syndrome  
- Pre‑excitation Syndromes  
- Obesity (Class III)  
- Critical Care / Acute Medical Illness or Surgery  
- Hyperthyroidism  
- Pulmonary Disease  
- Pregnancy  
- Cardio‑Oncology (anticoagulation considerations)  
- Chronic Kidney Disease (CKD) / Kidney Failure  
- Liver Disease (anticoagulation considerations)  

These terms encompass the major clinical concepts, populations, and therapeutic strategies addressed in the guideline related to heart disease.

Page 4 Extracted Terms:
- Atrial fibrillation (AF)  
- Stages of atrial fibrillation  
- Risk factor modification  
- Obesity  
- Weight loss  
- Physical activity  
- Smoking cessation  
- Alcohol moderation  
- Hypertension  
- Comorbidities  
- CHA₂DS₂‑VASc score  
- Thromboembolic event risk  
- Stroke  
- Systemic embolism  
- Ischemic stroke  
- Early rhythm control  
- Sinus rhythm  
- AF burden  
- Catheter ablation  
- Heart failure with reduced ejection fraction (HFrEF)  
- Device‑detected atrial fibrillation  
- Implantable devices  
- Wearable devices  
- Left atrial appendage occlusion devices  
- Anticoagulation  
- Class I indication  
- Class IIa recommendation  
- Cardiovascular disease  
- Cardiovascular health  
- Clinical risk scores  
- Shared decision‑making  


Page 5 Extracted Terms:
- Atrial fibrillation  
- Cardiovascular disease  
- Heart disease  
- Cardiovascular  
- ACC/AHA Joint Committee on Clinical Practice Guidelines  
- Guideline‑directed management and therapy (GDMT)  
- Evidence‑based methodology  
- Systematic review  
- Randomized controlled trials (RCTs)  
- Pharmacologic treatment  
- Procedural treatment  
- Diagnostic testing  
- Drug treatment regimens  
- Devices (medical devices)  
- Treatment strategy  
- Clinical evaluation  
- Clinical implementation  
- Shared decision‑making  
- Patient engagement  
- Adherence to recommendations  
- Cost‑value analysis  
- Knowledge chunk format  
- Flow diagrams  
- Evidence review committee  
- Methodology manual  
- RWI (relationships with industry)

Page 6 Extracted Terms:
atrial fibrillation
congenital heart disease
hypertrophic cardiomyopathy
valvular heart disease
coronary artery disease
chronic coronary syndromes
chronic kidney disease
heart failure
arrhythmias in pregnancy
left atrial appendage occlusion
left atrial appendage exclusion
catheter ablation
electrical cardioversion
amiodarone therapy
rate control
rhythm control
thromboembolism
Wolff‑Parkinson‑White syndrome
cardiac surgical procedures
anticoagulant therapy
rhythm monitoring
obesity
smoking
alcohol consumption
caffeine intake
sleep disorders
dietary factors
physical fitness
diabetes mellitus
congenital heart defects
genetic factors influencing heart disease
social determinants of health
stroke and transient ischemic attack prevention (as a cardiac risk management strategy)

Page 7 Extracted Terms:
**Heart‑disease–related terms extracted from the text**

- **ACE** – angiotensin‑converting enzyme  
- **ACHD** – adult congenital heart disease  
- **ACS** – acute coronary syndrome  
- **AF** – atrial fibrillation  
- **AFL** – atrial flutter  
- **AHRE** – atrial high‑rate episodes  
- **AP** – accessory pathway  
- **APT** – antiplatelet therapy  
- **ARB** – angiotensin receptor blocker  
- **AT** – atrial tachycardia  
- **AVNA** – atrioventricular nodal ablation  
- **BiVP** – biventricular pacing  
- **CABG** – coronary artery bypass graft surgery  
- **CAD** – coronary artery disease  
- **CCD** – chronic coronary disease

Page 8 Extracted Terms:
**Key heart‑disease terms found in the guideline excerpt**

- CHADS2  
- CHA₂DS₂‑VASc  
- CHD (congenital heart disease)  
- CHF (congestive heart failure)  
- CRT (cardiac resynchronization therapy)  
- CVD (cardiovascular disease)  
- DAT (dual antithrombotic therapy)  
- DOAC (direct oral anticoagulant)  
- EF (ejection fraction)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- HFrEF (heart failure with reduced ejection fraction)  
- ICD (implantable cardioverter‑defibrillator)  
- LA (left atrium)  
- LAA (left atrial appendage)  
- LAAO (left atrial appendage occlusion)  
- LV (left ventricle)  
- LVEF (left ventricular ejection fraction)  
- MI (myocardial infarction)  
- MRA (mineralocorticoid receptor antagonist)  
- NYHA (New York Heart Association)  
- OAC (oral anticoagulant)  
- PAC (premature atrial contraction)  
- PAD (peripheral artery disease)  
- PCI (percutaneous coronary intervention)  
- PH (pulmonary hypertension)  
- PHPVD (pulmonary hypertension with pulmonary vascular disease)  
- PITP (pill‑in‑the‑pocket)  
- pLAAO (percutaneous left atrial appendage occlusion)  
- PV (pulmonary veins)  
- PVI (pulmonary vein isolation)  
- RV (right ventricle)  
- RVP (right ventricular pacing)  
- SVT (supraventricular tachycardia)  
- TEE (transesophageal echocardiogram)  
- TIA (transient ischemic attack)  
- VF (ventricular fibrillation)  
- VHD (valvular heart disease)  
- VKA (vitamin K antagonist)  
- VT (ventricular tachycardia)  
- WPW (Wolff‑Parkinson‑White)

Page 9 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Sudden cardiac death  
- Cardiovascular disease (CVD)  
- Arrhythmia  
- Cardiovascular risk factors  
- Electrocardiographic biomarkers  
- Imaging biomarkers  
- Circulating biomarkers  
- Prevention (of AF and related cardiovascular conditions)  
- Screening (for AF)  
- Rate control therapy  
- Rhythm control therapy  
- Morbidity related to AF and other cardiac events  
- Mortality risk associated with AF and cardiovascular conditions  
- Atrial fibrillation classification (stages of disease progression)

Page 10 Extracted Terms:
- Atrial Fibrillation (AF)  
- Atrial Tachycardia (AT)  
- Macroreentrant atrial arrhythmias  
- Microreentry circuit  
- Stroke risk assessment  
- Rate‑control strategy  
- Rhythm‑control strategy  
- AF burden  
- Comorbidities  
- Modifiable risk factors  
- Symptom management  
- Screening for all risk factors (e.g., HEAD 2 TOES)  
- SOS (Symptom‑management framework)  
- 4 As (Access to All Aspects of care)

Page 11 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Macroreentrant atrial tachycardia (AT)  
- Cavotricuspid isthmus–dependent AFL (CTI‑dependent AFL)  
- Reverse typical AFL (clockwise circuit)  
- Atypical AFL / non‑cavotricuspid isthmus–dependent macroreentrant AT  
- Sawtooth flutter waves (ECG finding)  
- Tricuspid annulus  
- Pulmonary veins (PVs) of the left atrium (LA)  
- Pulmonary vein ectopy / ectopic action potentials  
- Sinoatrial node  
- Interstitial fibrosis (conduction heterogeneity)  
- Tachycardia runs (atrial ectopy)  
- Structural abnormalities of cellular connections  
- Electrophysiological abnormalities (electrical remodeling)  
- Calcium (Ca²⁺) handling abnormalities  
- Triangulated, shortened action potentials (pro‑arrhythmic)  
- Genetic, environmental, and metabolic etiologies of arrhythmia  
- Electrocardiogram (ECG)  
- Age‑standardized global prevalence rates of AF and AFL  
- Global Burden of Disease (GBD) study references  
- Macroreentrant circuit  
- Tricuspid valve/isthmus  
- Counterclockwise and clockwise reentrant directions  
- Pulmonary vein‑driven AF genesis (Haïssaguerre et al. finding)

Page 12 Extracted Terms:
- Atrial fibrillation (AF)  
- Incident atrial fibrillation  
- Risk of AF  
- Advancing age  
- Smoking  
- Sedentary lifestyle  
- Elite athletes / extreme exercise  
- Physical activity / exercise  
- Alcohol consumption  
- Alcohol‑related AF episodes  
- Obesity  
- Body mass index (BMI)  
- Childhood BMI  
- Height  
- Hypertension  
- Systolic blood pressure (SBP)  
- Diastolic blood pressure (DBP)  
- Blood‑pressure control, including intensive SBP <120 mm Hg  
- Renal denervation (for AF)  
- Mineral‑corticoid receptor antagonists (for AF)  
- Pulse pressure  
- Resting heart rate (J‑shaped relationship with AF)  
- Heart rate (resting, per‑5‑bpm increments)  
- Low‑risk favourable metrics (LRFM) programme  
- Circulation (journal reference)  
- Diagnosis and management guidelines (for AF)

Page 13 Extracted Terms:
**Key terms related to heart disease extracted from the guideline text:**

1. Diabetes mellitus  
2. Cardiovascular disease  
3. Heart failure (HF)  
4. Coronary artery disease (CAD)  
5. Myocardial infarction (MI)  
6. Valvular heart disease (VHD)  
7. Significant heart murmur  
8. Cardiac surgery (e.g., CABG, valve replacement, aortic aneurysm repair)  
9. Chronic kidney disease (CKD) – systemic condition with cardiovascular impact  
10. Obstructive sleep apnea (OSA)  
11. Thyroid disease – hyperthyroidism  
12. Sepsis (systemic infection with cardiovascular implications)

Page 14 Extracted Terms:
- Atrial fibrillation (AF)  
- PR interval  
- Left ventricular hypertrophy (LVH)  
- Natriuretic peptides (BNP)  
- C‑reactive protein (CRP)  
- Interleukin‑6 (IL‑6)  
- Tumor necrosis factor‑α (TNF‑α)  
- DUSP13  
- FKBP7  
- Spondin‑1  
- Interleukin‑6 receptor (IL‑6R)  
- TNF‑superfamily member 12 (TNFS12)  
- Lipoprotein(a) [Lp(a)]  
- Left atrial (LA) size  
- LA anterior‑posterior dimension  
- LA end‑diastolic volume  
- LA emptying fraction  
- LA ejection fraction  
- Left ventricular posterior wall thickness  
- Genetic susceptibility to AF (polygenic risk score)  
- Surgical left atrial reduction (with cardiac surgery or AF ablation)

Page 15 Extracted Terms:
Atrial fibrillation (AF)  
Heart failure (HF)  
Valvular heart disease (VHD)  
Coronary artery disease (CAD)  
Hypertrophic cardiomyopathy  
Obstructive sleep apnea (OSA)  
Sleep‑disordered breathing (SDB)  
Atherosclerotic cardiovascular disease (ASCVD)  
Left atrial (LA)  
Left ventricular (LV)  
Left ventricular hypertrophy (LVH)  
Brain natriuretic peptide (BNP)  
Electrocardiogram (ECG)  
Coronary artery bypass graft (CABG)  
Blood pressure (BP) – systolic (SBP) and diastolic (DBP)  
Body mass index (BMI)  
Chronic kidney disease (CKD)  
L-type Ca²⁺ current  
IK1 (inward rectifier K⁺ current)  
Connexin (gap junction protein)  
Reentry (arrhythmic circuit)  
Inflammatory state  
Older age (aging)  
Genetics / heritability  
Family history of AF  
Mendelian randomization (MR) findings  
Genome‑wide association study (GWAS) loci  
Socioeconomic status (SES) – adverse influence on AF risk  
Population attributable fraction (PAF) for AF  

These terms capture the key cardiovascular and electrophysiological concepts discussed in the guideline excerpt.

Page 16 Extracted Terms:
- Atrial fibrillation (AF)  
- Calcium mishandling  
- Cardiac remodeling  
- Sarcoplasmic reticulum calcium load  
- Ryanodine receptor dysfunction  
- Sarcoplasmic reticulum calcium ATPase (SERCA)  
- Phospholamban regulation  
- Sarcolipin regulation  
- Intracellular sodium overload  
- Calcium‑calmodulin II (CaMKII) activation  
- Late sodium current  
- Cardiac glycosides  
- Sodium‑calcium exchanger (NCX)  
- Oxidative stress  
- Inflammatory signalling  
- CaMKII‑mediated hyperphosphorylation of ryanodine receptor 2  
- Spontaneous diastolic Ca²⁺ leak  
- Delayed afterdepolarizations (DADs)  
- Premature atrial contractions (PACs)  
- Left atrial (LA) volume  
- N‑terminal pro‑b-type natriuretic peptide (NT‑proBNP)  
- LA emptying function  
- Pulmonary vein (PV) isolation  
- Pulmonary veins (PVs) as AF drivers  
- Effective refractory period (ERP)  
- Conduction velocity slowdown  
- Dispersion of repolarization  
- Cardiac re‑entry circuits  
- Atrial cardiomyopathy  
- Atrial structural abnormalities  
- Atrial myopathy  
- Interstitial changes  
- Myofibroblast activity  
- Collagen deposition  
- Fibrofatty deposits  
- Altered ion‑channel expression  
- Calcium signalling pathways  
- Contractility impairment  
- Inflammatory infiltrates  
- Myeloperoxidase (MPO) activity  
- Interstitial fibrosis  
- Prothrombotic changes in the LA  
- von Willebrand factor (vWF)  
- Vascular cell adhesion molecule‑1 (VCAM‑1)  
- Monocyte chemoattractant protein‑1 (MCP‑1)  
- Thrombus formation risk  
- Ischemic stroke risk  
- Hemodynamic overload  
- Aortopulmonary arteriovenous shunt  
- Atrial dilation  
- Atrial myocyte hypertrophy  
- Extracellular matrix remodeling  
- Vascular dysfunction  
- Atrial ectopy  
- Atrial ectopic beats  
- AF initiation triggers  
- Electrophysiological remodeling  
- Action‑potential alternans  
- Age‑related susceptibility to AF  
- Atrial electrophysiology abnormalities  
- Ventricular–atrial coupling  
- Electrogenic action of the sodium‑calcium exchanger  
- Sarcoplasmic reticulum dysfunction in AF  
- Late phase sodium currents  
- Ca²⁺ leak mechanisms  

These terms capture the key concepts and biomarkers discussed in the clinical guideline excerpt for heart‑related disease, particularly atrial fibrillation and its underlying pathophysiology.

Page 17 Extracted Terms:
- Atrial fibrillation (AF)  
- Clinical AF  
- Subclinical AF  
- First‑detected AF  
- Paroxysmal AF  
- Persistent AF  
- Long‑standing persistent AF  
- Permanent AF  
- AF burden  
- AF episode  
- Atrial high‑rate episodes  
- AF (atrial fibrillation)  
- Valvular AF  
- Non‑valvular AF  
- Lone AF  
- Atrial tachyarrhythmia  
- Atrial interstitial collagen  
- Atrial contraction  
- Thromboembolism risk  
- Calcium overload  
- Calcium current  
- Late sodium current (INa,L)  
- Oxidative stress  
- Reactive oxygen species  
- Inflammatory signaling  
- Inflammatory cytokines  
- Oxidative‑stress‑associated kinases (e.g., CaMKII, Jun‑kinase)  
- Nuclear factor‑kappa B (NF‑κB)  
- NLRP3 inflammasome  
- Fibrosis  
- Fibroblast activation  
- Renin–angiotensin–aldosterone system (RAAS)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin‑II receptor blockers  
- Hypertension  
- Obesity  
- Metabolic stress  
- Myofilament protein degradation  
- Atrial dilation  
- Atrial remodeling  
- Electrocardiographic abnormalities (irregular R‑R intervals, absent P waves, fibrillatory waves)  
- 12‑lead ECG  
- Wearable ECG monitoring  
- Implantable loop recorders  
- Pacemakers and defibrillators  
- Stroke risk reduction therapy  
- Vitamin K antagonists (e.g., warfarin)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- Prosthetic heart valves  
- Native valvular heart disease, excluding mitral stenosis  
- Structural heart disease (implicit in definitions of lone AF)  
- Atherosclerosis (mentioned in context of cardiovascular pathology)  

These terms collectively capture the key concepts and conditions related to heart disease as presented in the guideline text.

Page 18 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Atrial fibrillation (AF)  
- Persistent atrial fibrillation  
- Atrial flutter  
- Macroreentrant atrial tachycardia  
- Typical atrial flutter  
- Reverse‑typical atrial flutter  
- Low‑right atrial isthmus flutter  
- Scar‑mediated reentrant tachycardia  
- Left mitral isthmus flutter  
- Atrial substrate  
- Atrial refractory period  
- Conduction velocity  
- Heterogeneous conduction velocity  
- Repolarization duration  
- Atrial fibrosis (interstitial)  
- Atrial fatty infiltration (adipose)  
- Electrophysiologic remodeling  
- Autonomic nervous system (ANS)  
- Sympathetic efferent stimulation  
- Parasympathetic stimulation  
- Noradrenaline (norepinephrine)  
- β‑adrenergic receptor activation  
- L‑type calcium channel activity  
- Inward current (automaticity / early afterdepolarization)  
- Calcium overload  
- Ryanodine receptor dysfunction  
- Delayed afterdepolarization  
- Acetylcholine‑activated inward rectifying K⁺ channel (IKACh)  
- NLRP3 inflammasome  
- NLRP3‑blocking drugs  
- Systemic inflammatory activation (post‑cardiac surgery)  

These terms capture the primary concepts related to atrial rhythm disorders, electrophysiologic mechanisms, autonomic influences, structural substrate, and inflammatory pathways discussed in the guideline text.

Page 19 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial sympathetic and parasympathetic hyperinnervation  
- Electrical fractionation  
- Atrial electrophysiology  
- Autonomic nervous system (ANS) dysfunction  
- Cardiac volume  
- Blood volume  
- Blood pressure homeostasis  
- Heart failure (HF)  
- Atrial dilatation / atrial remodeling  
- Genetics of atrial fibrillation  
- Genome‑wide association studies (GWAS) for AF  
- Genetic loci specific to AF  
- TTN (titin) loss‑of‑function variants  
- MYH7 (myosin heavy chain 7) variants  
- MYH6 (myosin heavy chain 6) variants  
- LMNA (lamin A/C) variants  
- KCNQ1 (potassium voltage‑gated channel subfamily Q member 1) variants  
- Inherited cardiomyopathy genes  
- Arrhythmia syndrome genes  
- NLRP3 (NOD‑LRR‑pyrin domain containing protein 3)  
- Renin‑angiotensin‑aldosterone system (RAAS)  
- Premature atrial contraction (PAC)  
- Substrate for re‑entry  
- Trigger for arrhythmic activity

Page 20 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Anticoagulation  
- Rate control  
- Rhythm control  
- Catheter ablation  
- Stroke‑risk reduction therapies  
- Guideline‑directed medical therapy (GDMT)  
- Heart failure (HF)  
- Left atrium (LA)  
- Autonomic nervous system (ANS)  
- Heart rate variability (HRV)  
- Quality of life (QOL)  
- Social determinants of health (SDOH)  
- Health inequities and barriers to care  



Page 21 Extracted Terms:
- Atrial fibrillation (AF)  
- Anti‑arrhythmic drugs  
- Catheter ablation  
- Oral anticoagulation (OAC)  
- Direct oral anticoagulant (DOAC)  
- Cardioversion  
- Heart failure (HF)  
- Stroke (thromboembolic event)  
- Bleeding (anticoagulant‑related bleeding)  
- Left atrial appendage occlusion (LAAO)  
- CHARGE‑AF risk prediction model  
- C2HEST score (coronary artery disease, hypertension, elderly, systolic HF, etc.)  
- Coronary artery disease (CAD)  
- Hypertension  
- Systolic heart failure  
- Incident atrial fibrillation  
- Risk stratification and population screening for AF  
- Guideline for the Diagnosis and Management of Atrial Fibrillation (2023)  

(These terms capture the major heart‑disease concepts referenced in the text.)

Page 22 Extracted Terms:
**Heart‑disease–related terms extracted from the guideline text**

- Atrial fibrillation (AF)  
- Ischemic stroke  
- Systemic embolism  
- Transthoracic echocardiogram  
- Electrocardiogram (ECG)  
- Thyroid disease (hyperthyroidism)  
- Coronary artery disease (CAD)  
- Chronic obstructive pulmonary disease (COPD)  
- Hypertension  
- Systolic heart failure (HF)  
- Elderly (≥ 75 years)  
- Systolic blood pressure  
- Diastolic blood pressure  
- Smoking  
- Diabetes mellitus  
- Myocardial infarction  
- Acute coronary syndrome (ACS)  
- CHARGE‑AF risk score  
- C2HEST risk score  
- Cardiac structure and function  
- Valve function  
- Chamber size / thickness  
- Cardiac monitoring (intermittent/continuous)  

These are the principal cardiovascular concepts, diagnostic modalities, risk factors, and clinical endpoints discussed in the provided text.

Page 23 Extracted Terms:
- Atrial fibrillation (AF)  
- Right ventricular (RV) pressure  
- Left ventricular ejection fraction (LVEF)  
- Anti‑arrhythmic drug therapy  
- Rhythm control therapies  
- Catheter ablation  
- Strain imaging  
- Infiltrative cardiomyopathy (e.g., amyloidosis)  
- Echocardiography  
- Left atrial (LA) size and function  
- LA compliance  
- AF recurrence  
- LA strain  
- LA volume / left atrial volume  
- Chronic kidney disease (CKD)  
- Liver dysfunction  
- Hyperthyroidism  
- Electrolyte abnormalities  
- Diuretics  
- Stroke risk  
- Bleeding risk  
- Valvular disease  
- Myocardial ischemia  
- Acute coronary syndrome (ACS)  
- Pulmonary embolism (PE)  
- Rhythm monitoring tools  
- Electrocardiographic monitoring  
- Implantable cardiac monitors  
- Intracardiac rhythm devices  
- Atrial pacemaker lead  
- Systemic thromboembolic event  
- Consumer‑accessible electrocardiographic devices  
- Smartwatches  
- Photoplethysmography (PPG)  
- Standard 12‑lead ECG  
- Continuous loop‑recording ECG monitors  
- Implantable loop recorder  
- Cardiac rhythm management devices with atrial lead (pacemakers, defibrillators)  
- Handheld ECGs  
- Automated algorithms for AF detection  
- AF frequency, duration, burden  
- AF detection from atrial lead  
- AF‑related stroke risk prediction  
- AF‑related thromboembolic risk  
- Implantable cardiac monitor sensitivity for AF  
- AF diagnostic accuracy  
- AF monitoring burden estimation  
- Cardiac rhythm monitoring recommendations  
- AF management guidelines  
- Right ventricular/left ventricular function parameters  
- Cardiac imaging markers for cardiomyopathy  
- Electrolyte monitoring in AF patients  
- Risk factor evaluation for AF complications  
- Therapeutic decision‑making in AF  
- Cardiac evaluation in asymptomatic AF  
- Assessment of ischemic myocardium in AF patients  
- AF recurrence predictors after ablation  
- Electrocardiographic tracing interpretation  
- Photoplethysmographic AF inference  
- Handheld ECG early detection of recurrent AF  
- Implantable loop recorder clinical yield in AF detection  

(These terms capture the key heart‑disease concepts, diagnostic tools, therapies, risk factors, and monitoring strategies discussed in the text.)

Page 24 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial high‑rate episodes (device‑detected)  
- Cardiac rhythm devices with atrial leads  
- Anticoagulation (oral anticoagulation)  
- Stroke (incl. cardioembolic stroke)  
- Cryptogenic stroke  
- Implantable cardiac monitors  
- External cardiac monitors  
- Electrocardiographic tracings / ECG  
- Continuous wearable monitors  
- Photoplethysmography (smartphone / smartwatch)  
- Automated algorithm detection of AF  
- Cardioverter/ablation for AF  
- Quality of life (AF‑related)  
- Lifestyle and risk factor modification (LRFM) for AF  
- Obesity (weight, BMI)  
- Physical inactivity / sedentary lifestyle  
- Alcohol consumption (moderate, binge drinking)  
- Smoking (active tobacco use)  
- Diabetes mellitus  
- Hypertension (high blood pressure)  
- Cannabis use  
- Cocaine use  
- Methamphetamine use  
- Opioid use  
- High‑intensity endurance training (≥3 h/day)  
- J‑curve risk pattern for vigorous activity  
- Risk prediction models for AF  
- Population screening / risk stratification  
- Guideline‑directed medical therapy (GDMT) for cardiovascular risk factors  

Page 25 Extracted Terms:
- Atrial fibrillation (AF)  
- Arrhythmia  
- AF symptoms  
- AF burden  
- AF recurrence  
- Sinus rhythm  
- Obesity  
- Overweight  
- Body mass index (BMI)  
- Weight loss  
- Diabetes (type 1 and type 2)  
- Glucose control  
- Hypertension  
- Blood pressure (BP)  
- Intensive BP control  
- Cardiovascular disease (CVD)  
- Heart failure (HF)  
- Mortality  
- Cardiac catheter ablation  
- Bariatric surgery  
- Randomized controlled trial (RCT)  
- Aerobic exercise  
- Moderate‑to‑vigorous exercise  
- Functional capacity  
- Quality of life (QOL)  
- Physical fitness  
- Risk factor management  
- Cardiometabolic risk  
- Exercise prescription  
- Ventricular rate control  
- Cardiovascular risk profile  

Page 26 Extracted Terms:
- Atrial fibrillation (AF)  
- AF recurrence  
- AF burden  
- AF ablation  
- Cardiac rehabilitation  
- Exercise training (high‑intensity aerobic, moderate‑intensity, extreme exercise)  
- Heart failure (HF)  
- Hospitalization  
- All‑cause mortality  
- Stroke  
- Cardiovascular disease (CVD)  
- Cardiovascular complications  
- Smoking cessation  
- Behavioral interventions for tobacco cessation  
- Pharmacotherapy for tobacco cessation  
- Guideline‑directed medical therapy (GDMT)  
- Warfarin therapy (therapeutic range)  
- Alcohol consumption  
- Alcohol abstinence / reduction (≤3 standard drinks per week)  
- Rhythm‑control strategy  
- Caffeine consumption  
- Caffeine abstention / triggers  
- N‑of‑1 trial (caffeine)  
- Structured comprehensive risk‑factor management  

Page 27 Extracted Terms:
**Key terms related to heart disease (as extracted from the guideline text)**  

- Atrial fibrillation (AF)  
- Caffeine consumption (including excessive intake and energy drinks)  
- Palpitations (symptom of AF)  
- Heart rhythm awareness  
- Cardiovascular disease (CVD)  
- Omega‑3 fatty acids  
- Vitamin D supplementation  
- Ascorbic acid (vitamin C) supplementation  
- Weight management (obesity, BMI reduction)  
- Low‑carbohydrate diets  
- Diabetes mellitus (type 1 and 2)  
- Cardiovascular mortality  
- Sudden cardiac death  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Catheter ablation (AF ablation)  
- Glycemic control (pre‑ablation, post‑ablation)  
- Hypertension (high blood pressure)  
- Blood pressure (BP) control / BP lowering  
- Renal denervation (renal sympathetic modulation)  
- Mineralocorticoid receptor antagonists (MRAs)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin II receptor blockers (ARBs)  
- Pulmonary vein isolation (PVI)  
- Integrated lifestyle and risk‑factor modification programs (LRFM)  
- AF burden (frequency/duration of atrial fibrillation episodes)  
- AF recurrence (post‑ablation or post‑treatment)  
- Stroke (ischemic events related to AF)  
- Anticoagulation therapy (stroke prevention in AF)  
- Stroke risk reduction (via BP control, anticoagulation)  
- Adverse cardiovascular outcomes (stroke, bleeding, mortality)  
- Pharmacologic agents for AF prevention (e.g., MRAs, ACEi/ARB)  
- Symptomatic atrial arrhythmia (post‑ablation)  
- Clinical trials (e.g., SMAC AF, ARIC study)  

These terms encompass the core clinical entities, risk factors, preventive strategies, treatments, and outcomes discussed in the guideline.

Page 28 Extracted Terms:
- Atrial fibrillation (AF)  
- Obstructive sleep apnea (OSA)  
- Sleep‑disordered breathing (SDB)  
- Sinus rhythm  
- Stroke  
- Thromboembolism  
- Heart failure (HF)  
- Left ventricular ejection fraction (LVEF)  
- Obesity  
- Alcohol use  
- Mineralocorticoid receptor antagonist  
- Statins  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin receptor blockers (ARBs)  
- Cardiac rehabilitation  
- Anticoagulation therapy  
- AF recurrence  
- AF burden  
- Cardioversion  
- Pulmonary vein isolation (PVI)  
- Comprehensive AF care  
- Nurse‑led AF clinics  
- Clinical care pathways  
- Electronic clinical decision support systems  
- RACE 3 trial  
- RACE 4 trial  
- SAFETY study  
- All‑cause mortality  
- Cardiovascular outcomes  

Page 29 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Thromboembolism  
- Anticoagulation  
- CHA2DS2‑VASc score  
- CHADS2 score  
- HAS‑BLED score  
- HEMORR2HAGES score  
- ATRIA score  
- GARFIELD‑AF score  
- Risk stratification  
- Risk score development  
- c‑index (discrimination)  
- Annual risk of stroke/bleeding  
- Bleeding risk  
- Hypertension  
- Renal disease  
- Liver dysfunction  
- Age (≥65 years, ≥75 years)  
- Labile INR  
- Elderly status  
- Drug/alcohol concomitancy  
- Ethanol abuse  
- Malignancy  
- Anemia  
- Platelet count/function  
- Fall risk  
- Congestive heart failure  
- Diabetes mellitus  
- Stroke/TIA history  
- Clinical decision‑support systems (CDS)  
- mAF‑App (mobile health technology)  
- CDS‑AF tool  
- Mobile health technology for AF  
- Educational interventions for providers/patients  
- Shared decision‑making (SDM)  
- Risk discrimination and calibration in prediction models  



Page 30 Extracted Terms:
- Atrial fibrillation (AF)  
- Ischemic stroke  
- Stroke prevention  
- Anticoagulation (OACs)  
- Oral anticoagulants (DOACs)  
- Vitamin K antagonists (VKAs)  
- Bleeding risk  
- Net clinical benefit  
- CHA2DS2‑VASc score  
- ATRIA score  
- GARFIELD‑AF score  
- HAS‑BLED score  
- HEMORR2HAGES score  
- Left atrial appendage occlusion (LAAO) devices  
- Congestive heart failure (CHF)  
- Hypertension  
- Renal disease  
- Diabetes mellitus  
- Current smoking  
- Previous stroke or transient ischemic attack (TIA)  
- Vascular disease  
- Dementia  
- Proteinuria  
- pro‑BNP (biomarker)  
- Left atrial appendage (LAA) function and anatomy  
- Electrocardiographic features  
- Antiplatelet medications  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Antithrombotic treatment  
- Thromboembolic events  
- Bleeding risk factors  
- Clinically relevant risk factors for AF management  
- Age‐related risk categories (≥85 y, 75‑84 y, 65‑74 y, <65 y)  
- Hypertension control  
- Anticoagulation and risk factor stratification tools (ATRIA, CHA2DS2‑VASc, GARFIELD‑AF)  
- The ARISTOTLE trial (Apixaban)  


Page 31 Extracted Terms:
Atrial fibrillation (AF)  
Stroke  
Thromboembolism  
Anticoagulation / Oral anticoagulation  
Bleeding risk  
HAS‑BLED score  
HEMORR2HAGES score  
ATRIA score  
Stroke‑risk scores (e.g., CHA₂DS₂‑VASc)  
Annual risk of stroke  
Net clinical benefit  
Stroke‑risk reduction therapy  
Paroxysmal AF  
Persistent AF  
Long‑standing persistent AF  
Permanent AF  
Thromboembolic events  
Stroke prevention  
Risk‑based selection of oral anticoagulation  
Clinical decision‑making regarding anticoagulation  
Bleeding‑risk scores (e.g., HAS‑BLED, HEMORR2HAGES, ATRIA)

Page 32 Extracted Terms:
- Atrial fibrillation (AF)
- Stroke
- Systemic embolism
- Oral anticoagulants (OAC)
- Warfarin
- Direct oral anticoagulants (DOACs)
- Vitamin K antagonists (VKA)
- International normalized ratio (INR)
- CYP2C9
- Renal function / glomerular filtration rate (GFR)
- Age
- Congestive heart failure (CHF)
- Hypertension
- Diabetes mellitus
- Stroke/TIA risk
- Vascular disease
- Female sex (sex category)
- Anemia
- Proteinuria
- Bleeding risk
- CHA2DS2‑VASc score
- CHADS2 score
- ATRIA score
- MCHA2DS2‑VASc score
- GARFIELD‑AF score
- Stroke prevention therapy
- Anticoagulation therapy
- Anticoagulant dosing
- Stroke risk scores
- Cardiovascular morbidity
- Cardiovascular mortality
- Long‑term follow‑up
- Stroke risk assessment
- Systemic embolism prevention
- Stroke risk reduction
- Heart disease risk factors  
- Cardiovascular health management

Page 33 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)
- Chronic atrial fibrillation
- Permanent/persistent AF
- Paroxysmal AF
- AF burden / AF duration
- Mechanical heart valve
- Rheumatic mitral stenosis
- Cardiovascular stroke
- Systemic thromboembolism
- Intracranial haemorrhage (ICH)
- Gastro‑intestinal bleeding
- Anticoagulation
- Direct oral anticoagulants (DOACs) – apixaban, dabigatran, edoxaban, rivaroxaban
- Warfarin
- Antiplatelet therapy
- Aspirin
- Clopidogrel
- Antithrombotic therapy guideline
- CHA₂DS₂‑VASc score (and its risk categories)
- Thromboembolic risk (annual %)
- Heart failure
  - Right‑sided failure (elevated central venous pressure, hepatomegaly, dependent edema)
  - Left‑sided failure (exertional dyspnea, coughing, fatigue, orthopnea, paroxysmal nocturnal dyspnea)
  - Cardiac enlargement, pulmonary venous congestion, gallop rhythm
- Hypertension (resting BP >140/90 mm Hg or treated)
- Diabetes mellitus (FPG ≥7.0 mmol/L or on hypoglycemic agents/insulin)
- Coronary artery disease (prior MI, angina, PCI, CABG)
- Peripheral vascular disease (claudication, aortic or limb interventions, arterial/venous thrombosis)
- Vascular disease (general)
- Age ≥65 y, ≥75 y
- Sex (female)
- Obesity (BMI ≥ 30 kg/m²)
- Hypertrophic cardiomyopathy (HCM)
- Reduced eGFR (<45 mL/min/1.73 m²)
- Proteinuria (>150 mg/24 h)
- Enlarged left atrial volume (≥73 mL) or diameter (≥4.7 cm)
- Cardiovascular risk factors (additional to CHA₂DS₂‑VASc)
- Re‑LY, ROCKET AF (pivotal DOAC trials)
- Anticoagulant target INR (2–3, risk above 4)

These terms encapsulate the principal cardiovascular conditions, therapies, and risk factors discussed in the guideline excerpt.

Page 34 Extracted Terms:
- Atrial Fibrillation (AF)  
- Atrial Flutter (AFL)  
- Valvular Heart Disease (VHD)  
- Stroke  
- Thromboembolism / Systemic Embolism  
- Intracranial Hemorrhage (ICH)  
- Anticoagulation  
- Vitamin K antagonists (e.g., warfarin)  
- Factor Xa inhibitors (DOACs)  
- Direct Oral Anticoagulants (DOACs)  
- CHA₂DS₂‑VASc risk score  
- CHADS₂ risk score  
- ATRIA risk score  
- GARFIELD‑AF risk score  
- Congestive heart failure / left‑ventricular dysfunction  
- Hypertension  
- Age ≥ 75 years  
- Age 65–74 years  
- Diabetes mellitus  
- Vascular disease  
- Stroke / Transient Ischemic Attack (TIA)  
- Thromboembolism history  
- Female sex (as a risk modifier)  
- Anemia  
- Renal disease  
- Elderly (age ≥ 75 years) – risk factor in ATRIA  
- Previous bleeding  
- AF burden (amount of atrial fibrillation)  
- Antiplatelet therapy  
- Systemic embolic events  
- Stroke‑risk scores (general term)  
- Clinical trials: ARISTOTLE, ENGAGE AF‑TIMI 48, RE‑LY, ARISTOTLE, ENGAGE AF‑TIMI 48, etc.

Page 35 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Systemic embolism  
- Hypertrophic cardiomyopathy  
- Mitral stenosis  
- Mechanical valve  
- Aortic stenosis  
- Mitral regurgitation  
- Bioprosthetic valve  
- Valve repair  
- Valvular heart disease (VHD)  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Vitamin K antagonists (VKAs)  
- Warfarin  
- International Normalized Ratio (INR)  
- Time in therapeutic range (TTR)  
- Intracranial hemorrhage (ICH)  
- Major bleeding  
- Antiplatelet therapy (APT)  
- Aspirin  
- Clopidogrel  
- Coronary artery disease (CAD)  
- Vascular disease  
- Myocardial infarction (MI)  
- CHADS2 score  
- Stroke risk threshold  
- Markov decision model  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- AVERROES trial  
- ACTIVEW trial  
- Stroke risk score  
- Therapeutic value of warfarin  
- Stroke prevention guidelines  
- Anticoagulation therapy  
- Stroke rate  
- Systemic embolism risk  
- Embolic risk  
- Antithrombotic options  
- Stroke prevention in AF  
- Stroke risk of DOACs vs warfarin  
- Stroke risk of antiplatelets vs warfarin  
- Anticoagulation threshold  
- Stroke risk stratification  
- Cardiac rhythm disorder  
- Cardiovascular disease  
- Heart disease management  
- Cardiac valvular pathology  
- Cardiovascular risk assessment  
- Cardio‑vascular event  
- Cardio‑vascular outcome  
- Cardio‑vascular trial  
- Cardio‑vascular meta‑analysis  
- Cardio‑vascular guideline  
- Heart disease terminology  

*(All terms are directly drawn from the guideline text and pertain to heart disease concepts and therapies.)

Page 36 Extracted Terms:
- Atrial fibrillation (AF)  
- Anticoagulants  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Aspirin (antiplatelet therapy)  
- Stroke prevention  
- Cardioembolic stroke  
- Non‑cardioembolic stroke  
- Peripheral embolization  
- Major bleeding  
- Intracerebral hemorrhage (ICH)  
- Thromboembolism  
- Stroke risk  
- Intracranial hemorrhage  
- INR (international normalized ratio)  
- Time in therapeutic range (TTR)  
- Drug–drug interactions  
- CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir)  
- CYP3A4 inducers (rifampin, phenytoin, phenobarbital, carbamazepine, St. John’s wort)  
- P‑glycoprotein inhibitors  
- Renal function / creatinine clearance (CrCl)  
- Hepatic function  
- Mechanical valves  
- Anticoagulation dosing adjustment  
- Vitamin K intake  
- Monitoring of anticoagulation  
- Clinical trials (RCT)  
- Meta‑analysis  
- Stroke  
- Bleeding risk  
- Antithrombotic therapy  

(Each term is a key concept related to heart disease that appears in the provided guideline text.)

Page 37 Extracted Terms:
**Key Heart‑Disease‑Related Terms**

- Atrial Fibrillation  
- Oral Anticoagulants (OACs)  
- Vitamin K Antagonist (VKA)  
- Direct Thrombin Inhibitor  
- Factor Xa Inhibitor  
- Warfarin  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Edoxaban  
- CYP2C9  
- CYP1A2  
- CYP2C19  
- CYP3A4  
- CYP3A5  
- P‑glycoprotein (P‑gp)  
- Renal clearance (CrCl)  
- Body weight  
- Serum creatinine (SCr)  
- Dose adjustment  
- Drug–drug interaction  
- Dronedarone  
- Ketoconazole  
- Clarithromycin  
- Erythromycin  
- Ritonavir  
- Carbamazepine  
- Phenytoin  
- Rifampin  
- St. John’s wort  
- Half‑life  
- Excretion path (renal, hepatic, biliary)  
- Metabolism pathways (CYPs, P‑gp)

Page 38 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Transient ischemic attack (TIA)  
- Systemic embolism  
- Thromboembolism  
- Ischemic adverse events  
- Mechanical heart valve  
- Mitral stenosis  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Vitamin K antagonist  
- International normalized ratio (INR)  
- CYP3A4  
- P‑glycoprotein  
- Antiepileptic drugs  
- Nonsteroidal anti‑inflammatory drugs (NSAIDs)  
- Selective serotonin reuptake inhibitors (SSRIs)  
- Antimicrobial agents  
- Bleeding risk  
- Ischemic stroke  
- Net clinical outcome  
- All‑cause death  
- Implantable loop recorder  
- Silent AF  
- Dose adjustment  
- Underdosing  
- Overt dosing (over‑dosing)  
- Bioavailability  
- Food effect (high‑fat, high‑calorie meal)  
- Child‑Pugh score (liver function)  
- Creatinine clearance  
- INR goal (2–3)  
- Therapeutic INR range  
- Anticoagulant therapy  
- Antiplatelet therapy  
- Cardiovascular monitoring

Page 39 Extracted Terms:
- Atrial Fibrillation  
- Direct Oral Anticoagulant (DOAC)  
- HAS‑BLED score  
- Uncontrolled hypertension  
- Renal dysfunction (high serum creatinine, dialysis, kidney transplant)  
- Hepatic dysfunction (elevated bilirubin, ALT/AST/AP, cirrhosis)  
- Stroke (hemorrhagic or ischemic)  
- Bleeding history or predisposition  
- Labile INR (time in therapeutic range < 60%)  
- Elderly age (≥ 65 years)  
- Antiplatelet agents  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Excessive alcohol intake  
- Child‑Pugh classification (A, B, C)  
- Encephalopathy  
- Ascites  
- Total bilirubin  
- Albumin  
- International Normalized Ratio (INR)  
- Creatinine clearance (CrCL)  
- Liver disease severity (cirrhosis)

Page 40 Extracted Terms:
- Atrial Fibrillation (AF)  
- Occult (silent) Atrial Fibrillation  
- Device‑detected Atrial High‑Rate Episodes (AHRE)  
- Cryptogenic Stroke  
- Transient Ischemic Attack (TIA)  
- Stroke Risk  
- Systemic Embolism  
- CHA₂DS₂‑VASc score  
- Oral Anticoagulation  
- Antiplatelet Therapy (APT)  
- Cardiac Monitoring  
- Holter Monitor (24‑hour, 10‑day)  
- Implantable Loop Recorder (implantable recorder)  
- Extended Cardiac Monitoring  
- Shared Decision‑Making (SDM) framework  
- Stroke Prevention Guidelines  
- Cardiovascular Implantable Electronic Device (CIED)  
- Risk‑Stratification for Anticoagulation  
- Post‑stroke Mortality  
- Stroke‑Risk Reduction Therapy  
- Clinical Trial Evidence (e.g., EMBRACE, CRYSTAL‑AF, FIND‑AF, PER‑DIEM, ASSERT)  
- Diagnostic Work‑up for Cryptogenic Stroke  
- Stroke‑Risk Scores  
- Device‑Detected Atrial Arrhythmia  
- Stroke‑Prevention Therapy Thresholds  
- Duration of AF/AHRE (≤5 min, ≥24 h, intermediate)  
- Anticoagulation Indication Criteria  
  
These terms capture the core heart‑disease concepts addressed in the guideline excerpt.

Page 41 Extracted Terms:
- Atrial fibrillation (AF)  
- Subclinical atrial fibrillation (SCAF)  
- Atrial high‑rate episode (AHRE)  
- Oral anticoagulation (OAC)  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- CHA₂DS₂‑VASc score  
- Stroke (ischemic stroke)  
- Anticoagulation therapy (including VKA and non‑VKAs)  
- Thrombo‑embolism  
- Heart failure (HF)  
- Coronary artery disease (CAD)  
- Apixaban  
- Rivaroxaban  
- Electrocardiogram (ECG)  
- Device‑detected atrial fibrillation (device‑detected SCAF)  
- Subclinical AF burden/duration  
- Stroke risk stratification  
- Antithrombotic agents  
- Non‑Vitamin‑K antagonist oral anticoagulants trial (NOAH)  
- Apixaban for the Reduction of Thrombo‑Embolism in Patients With Device‑Detected Subclinical Atrial Fibrillation (ARTESiA)  
- COMMANDER‑HF (Rivaroxaban) trial  
- COMPASS (anticoagulation strategies) trial  

Page 42 Extracted Terms:
- Atrial fibrillation (AF)
- Atrial flutter (AFL)
- Atrial high‑rate episodes (AHREs)
- Subclinical atrial fibrillation
- Ischemic stroke
- Systemic embolism
- CHA₂DS₂‑VASc score
- Sex‑modified CHA₂DS₂‑VASc score
- Oral anticoagulation (OAC)
- Direct oral anticoagulants (DOACs)
- Warfarin
- Major bleeding
- Left atrial appendage (LAA)
- LAA occlusion (LAAO)
- Percutaneous LAAO (pLAAO)
- Surgical LAAO
- Watchman device (including Watchman FLX)
- Percutaneous closure devices
- Percutaneous atrial fibrillation interventions
- Catheter ablation / cardiac surgery for AF
- Implantable cardioverter‑defibrillator (ICD)
- Pacemaker
- Rhythm monitoring
- Procedural success
- Procedural risk
- Procedural complications
- Embolization
- Thrombus
- Stroke risk stratification
- Stroke prevention strategies
- Non‑valvular atrial fibrillation
- Hemorrhagic risk
- Anticoagulation contraindication
- Stroke risk reduction

These terms capture the central concepts and interventions discussed in the guideline excerpt related to heart disease, particularly atrial fibrillation and its management.

Page 43 Extracted Terms:
- Atrial Fibrillation  
- Left Atrial Appendage (LAA)  
- Left Atrial Appendage Occlusion (LAAO)  
- Surgical Left Atrial Appendage Occlusion (S‑LAAO)  
- Stroke  
- Systemic Embolism  
- Thromboembolism  
- Cardiovascular Mortality  
- All‑Cause Mortality  
- Major Bleeding  
- Non‑Major Clinically Relevant Bleeding  
- Anticoagulation (OAC)  
- Warfarin  
- Direct Oral Anticoagulants (DOACs)  
- CHA₂DS₂‑VASc Score  
- Watchman Device (Left Atrial Appendage Closure Device)  
- LAAOS III (Left Atrial Appendage Occlusion Study)  
- PROTECT AF Trial  
- PREVAIL Study  
- PRAGUE‑17 Trial  
- Cardiac Surgery  
- Coronary Artery Bypass Grafting (CABG)  
- Valve Surgery  
- Antithrombotic Regimen  
- Procedural Complications  
- Device‑Related Complications

Page 44 Extracted Terms:
- Atrial fibrillation (AF)  
- Left atrial appendage (LAA)  
- Left atrial appendage occlusion (LAAO)  
- Surgical left atrial appendage occlusion (S‑LAAO)  
- LAAOS III trial  
- CHA2DS2‑VASc score  
- Oral anticoagulation (OAC)  
- Dabigatran  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Factor Xa inhibitors  
- Idarucizumab  
- Andexanet alfa  
- Prothrombin complex concentrate (PCC)  
- 4‑factor PCC  
- Stroke  
- Systemic embolism  
- Thromboembolism  
- Ischemic events  
- Mortality  
- Coronary artery bypass grafting (CABG)  
- Valve surgery  
- Mechanical valve surgery  
- Off‑pump bypass  
- Left ventricular assist device (LVAD)  
- Congenital heart disease (CHD)  
- Surgical atrial fibrillation ablation  
- Cardiac transplant  
- Transesophageal echocardiography (TEE)  
- Cross‑clamp time  
- Bypass time  
- Chest tube output  
- Major bleeding  
- All‑cause rehospitalization

Page 45 Extracted Terms:
- Atrial fibrillation (AF)  
- Vitamin K antagonist (warfarin)  
- 4‑factor prothrombin complex concentrate (PCC)  
- Intravenous vitamin K  
- Fresh frozen plasma  
- Direct oral anticoagulants (DOACs):  
  - Dabigatran  
  - Apixaban  
  - Rivaroxaban  
  - Edoxaban  
- Idarucizumab (dabigatran reversal agent)  
- Andexanet Alfa (factor Xa inhibitor reversal agent)  
- Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban, enoxaparin)  
- Major bleeding / life‑threatening bleeding  
- Gastrointestinal bleeding  
- Hemostasis / bleeding cessation  
- Thrombosis events / thromboembolism  
- Activated PCC (activated prothrombin complex concentrate)  
- aPTT (activated partial thromboplastin time)  
- Prothrombin time (PT)  
- Anti‑factor Xa activity  
- Hemodialysis (used for dabigatran clearance)  
- FDA approval status for reversal agents  
- Emergency department visits for anticoagulant‑related bleeding  
- Multicenter cohort studies  
- Randomized controlled trials  
- Prospective observational studies  
- Shared decision making (SDM)  
- Multidisciplinary team approach (MDA)

Page 46 Extracted Terms:
- Atrial fibrillation  
- Venous thromboembolism (VTE)  
- Thromboembolism (arterial/venous)  
- Myocardial infarction  
- Ischemic stroke  
- Cardiac arrest  
- Sudden death  
- Life‑threatening/uncontrolled bleeding  
- Warfarin‑associated bleeding  
- Dabigatran  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Factor Xa inhibitors  
- Anticoagulation reversal agents  
- Idarucizumab  
- Andexanet alfa  
- Prothrombin complex concentrate (PCC)  
- Activated prothrombin complex concentrate (aPCC)  
- Vitamin K  
- International Normalised Ratio (INR)  
- Hemostasis/ hemostatic effectiveness

Page 47 Extracted Terms:
Atrial fibrillation  
Anticoagulation  
Direct oral anticoagulants (DOAC)  
Vitamin K antagonist (VKA)  
Warfarin  
Dabigatran  
Apixaban  
Edoxaban  
Rivaroxaban  
Mechanical heart valve  
Rheumatic heart disease  
Prosthetic heart valve  
Venous thromboembolism  
Intracranial hemorrhage (ICH)  
Intracranial bleeding  
Intraparenchymal bleeding  
Cerebral amyloid angiopathy  
Left atrial appendage occlusion (LAAO)  
Re‑initiation of anticoagulation  
Timing of anticoagulation resumption  
Thromboembolic events  
Stroke  
Major bleeding  
Minor bleeding  
Gastrointestinal bleeding  
Bleeding events per year  
Relative risk (RR)  
Hazard ratio (HR)  
Odds ratio (OR)  
Risk-benefit assessment  
Guideline recommendation  
Clinical trial (RE-LY)  
Clinical trial (ARISTOTLE)  
Clinical trial (ENGAGE AF‑TIMI 48)  
Clinical trial (ROCKET AF)  
Evidence level (C‑LD, B‑NR)  
Anticoagulation‑sparing strategies  
Risk of recurrent ICH  
Risk of thromboembolic recurrence  
Thromboelastography  
Bleeding risk score (e.g., HAS‑BLED)  
Stroke risk score (e.g., CHA₂DS₂‑VASc)  
Intracranial hemorrhage risk score  
Bleeding outcome metrics (per 100 patient‑years)  
Management of patients with AF and ICH.

Page 48 Extracted Terms:
- Atrial fibrillation  
- Mechanical heart valves  
- Rheumatic valvular disease  
- Anticoagulation therapy  
- Thromboembolic complications  
- Left atrial appendage (LAA) closure  
- Embolic events  
- Prothrombin complex concentrate (used in reversal of anticoagulation)

Page 49 Extracted Terms:
- Atrial fibrillation (AF)  
- Mechanical heart valve  
- Valvular disease  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- CHADS‑2/VASc score (CHA₂DS₂‑VASc)  
- Cerebral amyloid angiopathy  
- Intracranial hemorrhage (ICH)  
- Intracerebral hemorrhage (IPH)  
- Left atrial appendage (LAA)  
- LAA closure  
- PROTECT AF study  
- PREVAIL study  
- Epicardial LAA clipping  
- Anticoagulation‑related ICH  
- Hemorrhagic stroke  
- Thromboembolic complications  
- Systemic embolism  
- Stroke risk reduction  
- Anticoagulation resumption  
- Ischemic stroke  
- Thromboembolism  
- Stroke and mortality outcomes  
- Non‑valvular AF  
- Hypercoagulable state (e.g., active malignancy, genetic thrombophilia)  
- Poorly controlled hypertension  
- Genetic/acquired coagulopathy  
- Antiplatelet therapy (APT)  
- Rheumatic valve disease  
- Lobar intraparenchymal hemorrhage (IPH)  
- Disseminated cortical superficial siderosis  
- High CHA₂DS₂‑VASc score (>5)  
- Concomitant AF with valvular disease  
- Mechanical valve‑associated bleeding risk  
- Anticoagulation therapy (OACs)  
- VKA (warfarin) vs DOAC comparison  
- Stroke and mortality risk in AF patients with ICH  
- Anticoagulation timing after ICH (1–2 weeks, 7–8 weeks, 10–39 days)  
- Stroke prevention strategies in AF with high bleeding risk  
- Anticoagulation resumption window  
- Clinical guidelines for AF management in the presence of bleeding risk  
- Intracranial hemorrhage recurrence risk  

(These terms capture the primary heart‑disease concepts referenced in the text.)

Page 50 Extracted Terms:
- Atrial fibrillation (AF)  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Oral anticoagulation (OAC)  
- Periprocedural management  
- Invasive procedure  
- Surgery  
- Bridging anticoagulation  
- Low‑molecular‑weight heparin (LMWH)  
- Thromboembolism  
- Thrombotic risk  
- Bleeding risk  
- CHA₂DS₂‑VASc score  
- CHA₂DS₂‑VASc ≥2  
- Stroke  
- Transient ischemic attack (TIA)  
- Mechanical valve  
- Pacemaker implantation  
- Defibrillator implantation  
- Generator change  
- Cardiac catheterization  
- Transvenous lead extraction  
- Endoscopic procedures  
- Dental extraction  
- Ophthalmologic procedures  
- Percutaneous vascular access  
- Intra‑abdominal surgery  
- Pelvic surgery  
- Orthopedic surgery  
- Neurosurgical procedures  
- Cardiac surgery  
- Neuraxial anesthesia  
- Spinal surgery  
- Hepatic dysfunction  
- Renal dysfunction (CrCl)  
- Anemia  
- Antiplatelet therapy  
- Non‑steroidal anti‑inflammatory drugs (NSAIDs)  
- Alcohol use  
- International normalized ratio (INR)  
- Creatinine clearance (CrCl)  
- Thrombosis prevention  
- Anticoagulant interruption timing  
- High bleeding‑risk procedures  
- Low bleeding‑risk procedures  
- Guideline‑based risk stratification  
- Bleeding complications  
- Hemostasis  
- Cardiovascular disease terminology  
- Intraplaque hemorrhage (implied by bleeding risk contexts)

Page 51 Extracted Terms:
- Atrial fibrillation  
- Mechanical valve  
- Stroke / Transient ischemic attack (TIA)  
- Thromboembolism  
- CHADS₂ score  
- CHA₂DS₂‑VASc score  
- Direct oral anticoagulant (DOAC)  
- Warfarin  
- Unfractionated heparin  
- Low‑molecular‑weight heparin  
- Bridging anticoagulation  
- Pocket hematoma  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Lead extraction  
- Bleeding risk  
- Congestive heart failure  
- Hypertension  
- Diabetes mellitus  
- Vascular disease  
- Periprocedural anticoagulation  
- Anticoagulation interruption  
- Anticoagulation bridging  
- Device surgery  
- PAUSE study  
- BRUISE‑CONTROL trial

Page 52 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Anticoagulation (OAC)  
- Direct oral anticoagulants (DOACs) – apixaban, dabigatran, rivaroxaban, edoxaban  
- Vitamin K antagonists (VKAs) – warfarin  
- Bridging anticoagulation  
- Platelet antiplatelet therapy (APT)  
- Dual antithrombotic therapy (OAC + P2Y12 inhibitor)  
- Triple therapy (OAC + P2Y12 inhibitor + aspirin)  
- Periprocedural events  
- Bleeding risk (low, high)  
- Thromboembolism (clinical, cardiovascular)  
- Stroke risk (high)  
- Percutaneous coronary intervention (PCI)  
- Acute coronary syndrome (ACS)  
- Coronary artery disease (CAD)  
- Mechanical heart valves  
- Valvular heart disease  
- Low‑molecular‑weight heparin (LMWH) – dalteparin  
- PAUSE protocol  
- BRIDGE trial  
- PERIOP2 trial  
- Antithrombotic therapy guidelines  
- Renal function (impact on anticoagulant dosing)  
- Intravenous/intravenous drug hold (drug “hold” of 48 h)  
- Warfarin therapeutic window (INR > 1.9)  

These terms capture the key heart‑disease–related concepts discussed in the provided guideline excerpt.

Page 53 Extracted Terms:
- Atrial Fibrillation (AF)  
- Antithrombotic Regimen  
- Dual Antithrombotic Therapy (DAT)  
- Triple Therapy  
- Direct Oral Anticoagulant (DOAC)  
- Vitamin K Antagonist (VKA)  
- Aspirin  
- P2Y12 Inhibitor  
- Oral Anticoagulation (OAC)  
- Percutaneous Coronary Intervention (PCI)  
- Stent Thrombosis  
- Bleeding Risk / Clinically Relevant Bleeding  
- Major Adverse Cardiovascular Events (MACE)  
- Coronary Revascularization  
- Multivessel PCI  
- Complex Revascularization  
- Chronic Coronary Disease (CCD)  
- Coronary Artery Disease (CAD)  
- Stroke / Systemic Embolism Prevention  
- Antiplatelet Therapy (APT)  
- Randomized Controlled Trial (RCT)  
- Meta‑Analysis  
- PIONEER AF‑PCI  
- RE‑DUAL PCI  
- AUGUSTUS  
- ENTRUST‑AF PCI  
- WOEST  
- Antiplatelet and Anticoagulant Therapy  
- Clinical Outcome Assessment (e.g., relative risk, odds ratio, confidence interval)

Page 54 Extracted Terms:
- Atrial fibrillation (AF)  
- Coronary artery disease (CAD)  
- Peripheral artery disease (PAD)  
- Myocardial infarction (MI)  
- Stroke  
- Systemic embolism  
- Unstable angina  
- Coronary / peripheral revascularization  
- Anticoagulation therapy  
- Oral anticoagulation (OAC)  
- Direct oral anticoagulants (DOACs) – e.g., rivaroxaban  
- Warfarin  
- Antiplatelet therapy (APT)  
- Dual antiplatelet therapy (DAPT) – aspirin + P2Y12 inhibitor  
- Aspirin  
- P2Y12 inhibitors (e.g., clopidogrel, ticagrelor)  
- Major bleeding  
- Life‑threatening bleeding  
- Intracranial hemorrhage (ICH)  
- Composite primary outcome (stroke, systemic embolism, MI, unstable angina, death)  
- Clinical trial / randomized controlled trial (RCT)  
- Subgroup analysis  
- Meta‑analysis  
- WAVE (Warfarin Antiplatelet Vascular Evaluation) trial  
- ENGAGE AF‑TIMI 48 trial  
- ARISTOTLE trial  
- ROCKET AF trial  
- ORBIT‑AF II registry  
- AHA/ACC PAD guideline (2016)  
- Ankle‑brachial index (ABI) ≤ 0.90  
- Stent thrombosis  
- Acute limb ischemia  
- Critical limb ischemia  
- Lower‑extremity revascularization  
- Amputation  
- Bleeding risk vs. ischemic event risk  
- Non‑inferiority trial design  
- Risk of systemic thromboembolism in AF  
- Risk of major adverse cardiac events (MACEs) in PAD  
- Coronary intervention without revascularization  
- Antiplatelet monotherapy as standard of care for PAD.

Page 55 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke  
- Anticoagulation  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Apixaban  
- Rivaroxaban  
- Dabigatran  
- Dual therapy (OAC plus APT)  
- OAC monotherapy  
- Major adverse cardiac events (MACE)  
- Bleeding risk  
- Thromboembolism  
- Chronic kidney disease (CKD)  
- CKD stage 3  
- CKD stage 4  
- End‑stage renal disease (ESRD)  
- Hemodialysis  
- Calciphylaxis  
- Left atrial appendage occlusion (LAAO)  
- Antithrombotic therapy  
- Antiplatelet therapy (APT)  
- Coagulation monitoring (INR)  
- Renal function indices (eGFR, CrCl)  
- Stroke risk reduction  
- Bleeding risk reduction  
- Cardiovascular mortality  
- Non‑fatal stroke  
- Intracranial hemorrhage  
- Major bleeding  
- Ischemic stroke  
- Pivotal DOAC trials (e.g., AVERROES, ARISTOTLE, SPAF III)

Page 56 Extracted Terms:
- Atrial fibrillation (AF)  
- Valvular heart disease (VHD)  
- Rheumatic mitral stenosis  
- Moderate or greater mitral stenosis  
- Mechanical heart valve  
- Oral anticoagulation  
- Direct oral anticoagulant (DOAC)  
- Vitamin K antagonist (VKA)  
- Warfarin  
- Dabigatran  
- Apixaban  
- Edoxaban  
- Rivaroxaban  
- INVICTUS trial  
- RE‑ALIGN trial  
- PROACT Xa trial  
- CHA₂DS₂‑VASc score  
- Stroke  
- Systemic thromboembolism  
- Cardiovascular events  
- Myocardial infarction (MI)  
- Death  
- Bleeding complications  
- Thromboembolism  
- Renal function (CrCl)  
- Creatinine clearance  
- Bioprosthetic valve  
- Valve repair  
- Aortic stenosis  
- Mitral regurgitation  
- Blood clot  
- Drug interactions  
- Hemorrhage  
- On‑X aortic valve  
- Dabigatran Etexilate  
- Mechanical valve surgery  
- New‑onset AF (within 3 months of valve surgery)  
- Vascular cause (of death or embolism)  
- Stroke risk assessment  
- Anticoagulant therapy guidance


Page 57 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL) – typical & atypical  
- Catheter ablation (CTI‑dependent/CTI‑ablation)  
- Cardioversion  
- Oral anticoagulation / anticoagulant therapy  
- Thromboembolic risk / thromboembolism  
- Stroke (ischemic stroke)  
- Left atrial (LA) thrombus  
- Left atrial appendage (LAA) thrombus / LAA stunning  
- Atrial stunning  
- Chronic obstructive pulmonary disease (COPD)  
- Heart failure (HF)  
- LA enlargement  
- Inducible atrial fibrillation  
- Silent / subclinical AF  
- Thrombus formation  
- Spontaneous echocardiographic contrast (SEC)  
- Macroreentrant circuit  
- Isthmus (crista terminalis)  
- Counterclockwise AFL  
- Clockwise AFL  
- Atrial tachycardia (AT)  
- Intraprocedural anticoagulation strategies  
- Thromboembolic event rates  
- Risk‑adjusted annual risk (>2% risk for stroke)  
- Clinical risk profiling (CHA₂DS₂‑VASc, etc.)  
- Recurrence rate of AFL post‑ablation  
- Systemic embolism  
- Risk ratio & confidence interval (statistical outcomes)  
- Meta‑analysis of AF incidence post‑ablation  
- Asymptomatic AF detection (monitoring)  
- High‑risk patient populations (male predominance, older age)  
- Catheter ablation success rate  
- Anticoagulation discontinuation guidelines (post‑ablation)  

These terms capture the principal concepts, conditions, diagnostic and therapeutic considerations, and risk factors addressed in the guideline text.

Page 58 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Cavotricuspid isthmus (CTI)  
- CTI‑dependent atrial flutter  
- Catheter ablation  
- Stroke  
- Systemic thromboembolism  
- Thromboembolic event  
- Oral anticoagulation  
- Anticoagulation therapy  
- Non‑valvular atrial fibrillation  
- Implantable cardiac monitor  
- Ambulatory monitor  
- Wearable cardiac device  
- Left atrial enlargement  
- Inducible atrial fibrillation (at ablation)  
- Interatrial conduction time  
- Prolonged HV interval  
- Chronic obstructive pulmonary disease (COPD)  
- Obstructive sleep apnea  
- HATCH score (Hypertension, Age ≥ 75 years, TIA or stroke, COPD, Heart failure)  
- Hypertension  
- Age ≥ 75 years  
- Transient ischemic attack (TIA)  
- Heart failure  
- Cryptogenic stroke  
- Prolonged continuous monitoring  
- Long‑term follow‑up  

These terms capture the key heart‑disease concepts and clinical factors discussed in the text.

Page 59 Extracted Terms:
- Atrial fibrillation (AF)  
- Rate control (rate‑control strategies)  
- Rhythm control (rhythm‑control strategies)  
- Heart rate (resting heart rate, target heart rate)  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Cardiac mortality  
- Stroke  
- Systemic embolism  
- Bleeding (major bleeding)  
- Arrhythmic events (life‑threatening arrhythmias)  
- Quality of life (QOL)  
- Left ventricular ejection fraction (LVEF)  
- Sick sinus syndrome (tachycardia‑bradycardia form)  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Cardiovascular outcomes (all‑cause mortality, composite endpoints)  
- RACE II study  
- AFFIRM study  
- HOT CAFE trial  
- ORBIT‑AF trial  
- Atrial fibrillation follow‑up investigation (AFFIRM)  
- How to Treat Chronic Atrial Fibrillation (HOT CAFE)  
- Observational studies on AF and heart rate  

(Note: The list focuses on clinical terms and concepts specifically related to heart disease described in the guideline excerpt.)

Page 60 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Beta blockers  
- Nondihydropyridine calcium channel blockers (verapamil, diltiazem)  
- Digoxin  
- Amiodarone  
- Left ventricular (LV) systolic dysfunction  
- Heart failure with reduced ejection fraction (HFrEF)  
- Decompensated heart failure (HF)  
- Tachycardia‑induced cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Rapid ventricular rate control  
- Intravascular magnesium  
- Intravenous esmolol  
- Ventricular rate control guidelines  
- Atrial flutter (AFL)  

These terms capture the key heart‑disease entities and therapeutic agents discussed in the guideline excerpt.

Page 61 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Rate control  
- Atrioventricular (AV) nodal blockers  
- Antiarrhythmic agents  
- Intravenous magnesium (as rate‑control therapy)  
- Sinoatrial (SA) node  
- Atrioventricular node  
- Slow inward calcium channels  
- Calcium‑channel blockade (non‑dihydropyridine)  
- Beta‑adrenergic blockade  
- Intravenous diltiazem  
- Intravenous verapamil  
- Intravenous digoxin (digitalis glycoside)  
- Intravenous amiodarone  
- Intravenous esmolol  
- Oral beta‑blockers  
  - Metoprolol tartrate  
  - Metoprolol succinate  
  - Atenolol  
  - Bisoprolol  
  - Carvedilol  
- Propranolol (oral and IV)  
- Nadolol (oral)  
- Digitalis (digoxin) – renal clearance and toxicity at >1.2 ng/mL  
- Coronary artery bypass grafting (CABG) – context for rapid AF after surgery  
- Heart failure with reduced ejection fraction (HFrEF) – contraindication for diltiazem and verapamil  
- Heart rate metrics (e.g., heart rate >120 bpm, goal <90 bpm)  
- Hospital length of stay (as outcome of rate‑control efficacy)  

These terms capture the major concepts, pharmacologic classes, and clinical parameters related to heart disease discussed in the excerpt.

Page 62 Extracted Terms:
- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular dysfunction (LV dysfunction)  
- Left ventricular ejection fraction (LVEF)  
- Atrioventricular nodal blockers  
- Beta blockers  
- Diltiazem  
- Verapamil  
- Digoxin  
- Amiodarone (intravenous amiodarone)  
- Intravenous magnesium  
- Intravenous calcium channel blockers  
- Negative inotropic effects  
- Acute kidney injury (AKI)  
- Worsening heart‑failure symptoms (increased oxygen requirement, inotropic support)  
- Hypotension (drug‑induced)  
- Inotropic support  
- Rate control  
- Rhythm conversion (to sinus rhythm)  
- Ventricular rates  
- Intensive care unit (ICU) patients with cardiac rhythm issues  
- Mortality rate (in-hospital)  
- Hospitalized patients with AF and RVR  

These terms capture the key cardiovascular concepts addressed in the guideline text.

Page 63 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)
- Heart failure (HF)
- Heart failure with reduced ejection fraction (HFrEF)
- Left ventricular ejection fraction (LVEF)
- Long‑term rate control
- Ventricular rate
- B‑blocker (beta blocker)
- Nondihydropyridine calcium‑channel blocker
- Verapamil
- Diltiazem
- Digoxin
- Serum digoxin level / concentration
- Digoxin toxicity
- Narrow therapeutic range
- Cardio‑vacular events
- Dronedarone
- Electrocardiographic abnormalities (ECG/EKG)
- N‑terminal pro‑brain natriuretic peptide (NT‑proBNP)
- Quality of life (QOL)
- Hospitalization
- All‑cause mortality
- Arrhythmia‑related symptoms
- Emergency department length of stay
- Adverse events

These terms capture the essential clinical concepts, therapeutic agents, and outcome measures discussed in the guideline excerpt.

Page 64 Extracted Terms:
**Key terms related to heart disease**

- Atrial fibrillation (AF)  
- Rapid ventricular response (RVR)  
- Resting heart rate  
- Digoxin  
- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Left ventricular ejection fraction (LVEF) / EF < 40%  
- Heart failure with reduced ejection fraction (HFrEF)  
- Diltiazem  
- Multicenter Diltiazem Post‑infarction Trial (MDPIT)  
- Myocardial infarction (MI)  
- Dronedarone  
- PALLAS trial  
- ERATO trial  
- Atrioventricular nodal ablation (AVNA)  
- Pacemaker (PM)  
- His bundle pacing  
- Left bundle‑area pacing  
- Sudden death  
- Mortality  
- Stroke  
- Hospitalization for heart failure  
- Non‑dihydropyridine calcium channel blocker (NDCC)  
- Ventricular rate control  
- Quality of life (QOL)  
- Adverse events  
- Major vascular events  
- Rhythm control strategy  
- Rate‑control medications  
- Pacemaker lower‑rate programming (80–90 bpm)  
- Ventricular response reduction  
- Long‑term rate control in AF  
- Life‑table analysis for late HF  

These terms capture the principal diseases, interventions, clinical trials, pharmacologic agents, and outcomes discussed in the text.

Page 65 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Permanent atrial fibrillation  
- Atrioventricular nodal ablation (AVNA)  
- Right ventricular pacing (RVP)  
- Biventricular pacing (BiVP)  
- Heart failure (HF)  
- Ventricular fibrillation (VF)  
- Sudden cardiac death  
- Malignant arrhythmias  
- Bradycardia  
- QT prolongation  
- Heterogeneity of repolarization  
- Ejection fraction (EF)  
- New York Heart Association (NYHA) class  
- Conduction‑system pacing  
- His‑bundle pacing  
- Left‑bundle‑area pacing  
- 6‑minute walk test  
- Stroke  
- Hospitalization  
- Pacemaker implantation  
- Lead dislodgement  
- Lead failure  
- Cardiomyopathy  
- Cardiac performance  
- Quality of life (QOL)  

(These terms are directly related to heart disease or its clinical management.)

Page 66 Extracted Terms:
- Atrial fibrillation (AF)  
- Persistent atrial fibrillation  
- High‑burden atrial fibrillation  
- Left ventricular (LV) function  
- Ejection fraction (EF)  
- Reduced EF (<40%)  
- Reduced EF (<50%)  
- New‑onset AF (<1 year)  
- Left bundle area pacing  
- His bundle pacing  
- Atrioventricular nodal ablation (AVNA)  
- Conduction system pacing  
- Rhythm control therapy  
- Rate control therapy  
- Anti‑arrhythmic drugs (AADs)  
- Catheter ablation for AF  
- Cardiac ablation  
- Heart failure (HF)  
- Ischemia  
- Stroke  
- Mortality  
- Hospitalization (cardiac, HF, ACS)  
- Cardiac structural abnormalities  
- Dementia (AF‑related)  
- AF burden  
- Ventricular rates  
- New‑onset AF diagnostic trials (e.g., EAST‑AFNET 4)  
- RACE II study (lenient vs. strict rate control)  
- Quality of life (QOL) improvement  
- Cardiovascular death  
- Cardiac hospitalization  
- AF progression prevention  
- AF‑related symptoms  
- Modifiable cardiovascular risk factors  
- AF burden monitoring  
- Early rhythm‑control strategies  
- Rapid ventricular rate  
- Symptom‑based treatment decisions  
- Clinical studies supporting rhythm control (e.g., RACES, EAST‑AFNET 4)  
- Composite cardiovascular outcomes (death, stroke, hospitalization)

Page 67 Extracted Terms:
- Atrial fibrillation (AF)  
- Congestive heart failure (HF)  
- Cardiovascular death  
- Ischemic stroke  
- Hospitalization for ischemia or HF  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Amiodarone (arrhythmia‑directed therapy)  
- Cardiac arrhythmia  
- Left atrium (LA)  
- Left ventricular (LV) function  
- Composite primary endpoint (cardiovascular death, stroke, HF hospitalization)  
- Mortality rate  
- Quality of life (QOL) improvement  
- AF‑CHF trial  
- EAST‑AFNET 4 study  
- CABANA trial  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  
- Central venous access (in catheter ablation context)  
- Sinus rhythm maintenance  
- Healthcare resource utilization (ER visits, etc.)

Page 68 Extracted Terms:
- Atrial fibrillation (AF)  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Heart failure (HF)  
- Left ventricular dysfunction  
- Left atrial (LA) size  
- Sinus rhythm  
- Catheter ablation  
- CASTLE‑AF trial  
- AF‑CHF study  
- AF burden  
- AF progression  
- Stroke  
- Cardiovascular death  
- Hospitalization for heart failure  
- Asymptomatic atrial fibrillation  
- Symptomatic atrial fibrillation  
- EAST‑AFNET 4 trial

Page 69 Extracted Terms:
- Atrial fibrillation  
- Mitral regurgitation  
- Tricuspid regurgitation  
- Left atrial enlargement / left atrial size  
- Mitral annular dilation  
- Left atrial appendage thrombus  
- Left atrial appendage occlusion (LAAO)  
- Cardiac thrombus  
- Cardioversion (electrical)  
- Cardioversion (pharmacologic)  
- Anticoagulation therapy  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- CHA₂DS₂‑VASc score  
- Heart failure (HF)  
- Hemodynamic instability  
- Hemodynamic stability  
- Atrioventricular dyssynchrony  
- Atrial kick  
- Atrial myopathy  
- Atrial stunning  
- Prothrombotic state  
- Transesophageal echocardiography (TEE)  
- Rhythm control strategy  
- Rate control strategy  
- Intracardiac thrombus  
- Thromboembolic risk  
- Structural heart disease  
- Device‑related thrombus  
- Thromboembolism


Page 70 Extracted Terms:
- Atrial fibrillation (AF)  
- Cardioversion  
- Electrical cardioversion  
- Pharmacological cardioversion  
- Anticoagulation  
- Vitamin K antagonists (VKAs)  
- Direct oral anticoagulants (DOACs)  
- Thromboembolism  
- Thromboembolic risk  
- Intracardiac thrombus  
- Cardiac computed tomography  
- Delayed contrast‑enhanced imaging protocol  
- Transesophageal echocardiography (TEE)  
- Atrial dysfunction  
- Atrial stunning  
- Mechanical atrial systole  
- Left atrial appendage occlusion (LAAO)  
- Hemodynamically stable AF  
- Multicenter randomized clinical trial (ACUTE study)

Page 71 Extracted Terms:
- Atrial fibrillation (AF)
- Atrial myopathy
- Intracardiac thrombus
- Cardioversion (electrical cardioversion)
- Anticoagulation
- Vitamin K antagonist (VKA)
- Rivaroxaban (direct oral anticoagulant)
- Transesophageal echocardiography (TEE)
- Left atrial appendage (LAA)
- Left atrial appendage occlusion (LAAO)
- Peri‑cardioversion anticoagulation
- Thromboembolism
- Stroke
- Systemic embolism
- Device‑related thrombosis (e.g., Watchman, Lariat, pLAAO devices)
- Residual leak (≤5 mm, >5 mm)
- CHA2DS2‑VASc score
- Transcranial computed tomography (CT) imaging
- Clinical guidelines for AF management
- Clinical evidence from CLOT‑AF and X‑TRA studies
- Anticoagulant compliance and drug interactions
- Non‑adherence and subtherapeutic drug levels
- Post‑cardioversion thromboembolic risk
- Surgical ligation of the LAA
- Left atrial appendage thrombus resolution on follow‑up TEE
- Left atrial or Left atrial appendage thrombus (LA/ LAA)
- Thrombus detection before cardioversion
- Anticoagulation-naïve patients
- Anticoagulation-naïve management
- Thrombus resolution rates with VKA and rivaroxaban
- Acute vs delayed inadequate LAAO occlusion
- Imaging for assessment of LAAO efficacy
- Post‑procedural residual leak assessment
- Stroke/systemic embolism risk in LAAO patients
- Cardioversion safety guidelines (duration <48 h)

Page 72 Extracted Terms:
- Atrial fibrillation (AF)  
- Electrical cardioversion  
- Hemodynamic instability  
- Sinus rhythm  
- Ventricular fibrillation (VF)  
- CHA₂DS₂‑VASc score  
- Pericardioversion thromboembolic event  
- Anti‑arrhythmic drugs  
- Left atrial (LA) size  
- Transthoracic impedance  
- Electrode vector  
- Biphasic energy (≥200 J)  
- Sedation for cardioversion  
- Rhythm control strategy  
- Pharmacological cardioversion  
- AF duration  
- Heart rhythm disorders  
- AF recurrence  
- Cardioversion energy delivery  
- Cardiac rhythm restoration  

Page 73 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial fibrillation, persistent  
- Atrial fibrillation, new‑onset  
- Electrical cardioversion  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone  
- Flecainide  
- Propafenone  
- Procainamide  
- Biphasic waveform  
- Monophasic waveform  
- Shock energy (J)  
- Electrode vector orientation – anterior‑posterior / anterior‑lateral  
- Hemodynamically stable  
- Hemodynamic compromise  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced EF (HFrEF)  
- QT interval prolongation  
- Torsades de pointes  
- Defibrillation (dual‑defibrillator use)  
- Transthoracic impedance  
- Obesity (increased transthoracic impedance)  
- Pill‑in‑the‑pocket (PITP) approach  
- Atrial arrhythmia  
- Ventricular fibrillation (VF)

Page 74 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter  
- Heart failure with reduced ejection fraction (HFrEF)  
- Pharmacological cardioversion  
- Electrical cardioversion  
- Intravenous amiodarone  
- Intravenous ibutilide  
- Flecainide  
- Propafenone  
- Procainamide  
- Dofetilide  
- Oral amiodarone  
- Oral sotalol  
- Conversion to sinus rhythm  
- Bradycardia  
- Hypotension  
- QT prolongation  
- Torsades de pointes (TdP)  
- Ventricular tachycardia (VT)  
- Atrioventricular (AV) block  
- Exacerbation of HFrEF  
- Phlebitis  
- Neutropenia  
- Agranulocytosis  
- Thrombocytopenia  
- Rash  
- Nausea  
- Dizziness  
- Dyspnea  
- Visual disturbances  
- Taste disturbances  
- N-acetylprocainamide (NAPA)  
- Liver metabolism  
- Kidney excretion  
- Biliary excretion  
- Half‑life (range 9‑36 days)  
- Loading dose  
- Maintenance dose  
- Administration route (IV, oral, continuous infusion)

Page 75 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Direct current cardioversion / electrical cardioversion  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone (intravenous amiodarone)  
- Procainamide  
- Torsades de pointes  
- QT interval prolongation (QTc prolongation)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Magnesium infusion (prophylaxis for torsades de pointes)  
- Proarrhythmia  
- Post‑conversion bradycardia  
- Continuous electrocardiographic monitoring  
- Emergency department / acute care setting  
- Cardiac resuscitation  
- Intravenous (IV) drug administration  
- Cardiac rhythm conversion time (30–90 min vs 8–12 h)  

These terms capture the core concepts and interventions pertaining to heart rhythm disorders and their management.

Page 76 Extracted Terms:
**Key terms related to heart disease extracted from the guideline:**

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular ejection fraction (LVEF)  
- Myocardial infarction (MI)  
- Structural heart disease  
- Ventricular scar / fibrosis  
- Hyponatremia? (not in the excerpt)  
- Hypokalemia  
- Hypomagnesemia  
- QT interval prolongation  
- Torsades de pointes  
- Beta blockers  
- Nondihydropyridine calcium channel blockers  
- Antiarrhythmic drugs  
- Class IC antiarrhythmics – flecainide, propafenone  
- Class III antiarrhythmics – dofetilide, dronedarone, sotalol, ibutilide  
- Class IA antiarrhythmic – procainamide  
- Proarrhythmia  
- Hypotension  
- New York Heart Association (NYHA) functional classes III & IV heart failure  
- Decompensated heart failure  
- Conversion of AF to sinus rhythm  
- Long‑term maintenance of sinus rhythm (rhythm‑control strategy)  
- Kidney function (for dose adjustment and monitoring)  
- QT interval monitoring  

*These terms capture the primary clinical conditions, therapeutic agents, and monitoring considerations relevant to heart disease as discussed in the guideline.*

Page 77 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Supraventricular tachycardia (SVT)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- Myocardial infarction (MI)  
- Structural heart disease (scar or fibrosis)  
- Sinus rhythm  
- Maintenance of sinus rhythm  
- Beta‑blocker therapy  
- Atrioventricular nodal blocking agent  
- Sotalol (antiarrhythmic)  
- Amiodarone (antiarrhythmic)  
- Dofetilide (antiarrhythmic)  
- Flecainide (antiarrhythmic)  
- Propafenone (antiarrhythmic)  
- Dronedarone (antiarrhythmic)  
- Flec‑SL (short‑term vs. long‑term antiarrhythmic trial)  
- SAFIRE‑D study (dofetilide trial)  
- SAFE‑T trial (Sotalol vs. Amiodarone)  
- CTAF trial (Canadian Trial of Atrial Fibrillation)  
- EURIDIS study (European Trial in Atrial Fibrillation)  
- ADONIS study (American‑Australian‑African Trial)  
- QT interval prolongation  
- Torsades de pointes  
- Pulmonary fibrosis  
- Hypo‑ or hyperthyroidism  
- Elevated transaminases  
- Hepatotoxicity  
- Corneal microdeposits  
- Optic neuropathy

Page 78 Extracted Terms:
- Atrial fibrillation (AF)  
- Sinus rhythm  
- Sotalol  
- Advanced heart failure (HF)  
- Preserved heart function  
- CrCl (creatinine clearance)  
- Continuous electrocardiographic monitoring  
- Cardiac resuscitation  
- Intravenous sotalol  
- Cardiac Arrhythmia Suppression Trial (CAST)  
- Vaughan Williams class IC antiarrhythmic agents  
- Flecainide  
- Encainide  
- Mortality rate  
- Recent myocardial infarction (MI)  
- Left ventricular ejection fraction (LVEF) < 50%  
- CAST‑II  
- Moricizine  
- Cardiac Arrest Study Hamburg (CASH)  
- Propafenone  
- Structural heart disease  
- Heart failure with reduced ejection fraction (HFrEF)  
- Worsening heart failure  
- Dronedarone  
- Hospitalization due to heart failure (HF)  
- Arrhythmic death  
- New York Heart Association functional class (NYHA FC)  
- Left ventricular (LV)  
- Myocardial infarction (MI)  
- Intravenous (IV)  
- Heart failure (HF)

Page 79 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) functional class II, III, IV  
- Class III antiarrhythmic drugs  
- Class IC antiarrhythmic drugs  
- Dofetilide  
- Sotalol  
- Flecainide  
- Propafenone  
- Amiodarone  
- Torsades de pointes  
- QT interval prolongation / QTc prolongation  
- Proarrhythmia  
- Bradyarrhythmia  
- Ventricular fibrillation (VF)  
- Ventricular tachycardia (VT)  
- Electrocardiographic monitoring (continuous ECG)  
- Cardiac resuscitation  
- Renal function assessment (CrCl)  
- Renin‑angiotensin‑aldosterone system (RAAS) inhibitor therapy  
- Hyperkalemia  
- Intravenous antiarrhythmic therapy  
- Hospitalization for antiarrhythmic initiation  
- Outpatient antiarrhythmic therapy  
- SAFIRE‑D study  
- DIAMOND trial  
- SAFE‑T trial  
- AFFIRM trial (substudy)  
- Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFER‑D)  

These terms capture the key heart‑disease–related concepts presented in the guideline text.

Page 80 Extracted Terms:
- Atrial fibrillation  
- Maintenance of sinus rhythm  
- Amiodarone  
- Dofetilide  
- Dronedarone  
- IKr (rapid delayed rectifier K⁺ current)  
- IKs (slow delayed rectifier K⁺ current)  
- INa (sodium channel)  
- IKur (ultra‑rapid delayed rectifier K⁺ current)  
- Ito (transient outward K⁺ current)  
- ICa‑L (L‑type Ca²⁺ channel)  
- IKAch (acetylcholine‑activated K⁺ channel)  
- Non‑competitive β‑blocker  
- AV block (atrioventricular block)  
- Bradycardia  
- QT prolongation  
- Torsades de Pointes (TdP)  
- Hyperthyroidism  
- Hypothyroidism  
- Hepatotoxicity  
- Pulmonary fibrosis  
- Skin pigmentation (blue‑gray)  
- Photosensitivity  
- Peripheral neuropathy  
- Transaminase elevation  
- CYP2C9, CYP2D6, CYP3A (drug metabolism pathways relevant to cardiac drugs)  
- P‑gp (P‑glycoprotein) substrate/inhibitor activity  
- Drug‑drug interactions affecting cardiac rhythm (e.g., with warfarin, digoxin, statins, anti‑arrhythmics)  
- Renal excretion (CrCl‑dependent dosing for dofetilide)  
- Biliary excretion (liver metabolism of amiodarone)  
- Sinus rhythm (electrophysiological term)  
- Cardiac pharmacokinetics (loading vs. maintenance doses)

Page 81 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Sinus rhythm  
- Permanent pacemaker  
- Bradycardia  
- Hypotension  
- Syncope  
- Rapid atrial flutter (1:1 AFL)  
- Cardioversion  
- Class IC anti‑arrhythmic agents  
- Flexenide (flecainide)  
- Propafenone  
- Sotalol  
- PITP strategy (pulmonary‑influenced termination protocol)  
- AV nodal blocker  
- AV block  
- Proarrhythmia  
- QT prolongation  
- Torsades de pointes (TdP)  
- Ventricular tachycardia (VT)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Anti‑arrhythmic drug follow‑up  
- Mechanisms of action (INa inhibition, IKr inhibition, late INa augmentation)  
- Drug interactions (e.g., with amiodarone, digoxin, warfarin, statins)  
- CYP2D6 metabolism  
- Pharmacokinetics (half‑life, liver/kidney elimination, CrCl)  
- β‑blocker effects (used in sotalol)

Page 82 Extracted Terms:
Atrial fibrillation  
Amiodarone  
Amiodarone‑induced hypothyroidism  
Amiodarone‑induced hyperthyroidism  
Hepatic transaminase elevation  
Hepatotoxicity  
Pulmonary toxicity  
Interstitial lung disease  
Hypersensitivity syndrome  
Chest x‑ray  
Pulmonary function testing  
Diffusing capacity for carbon monoxide  
CT scan  
Corneal microdeposits  
Epithelial keratopathy  
Neurological toxicity  
Peripheral neuropathy  
Torsades de pointes  
Dofetilide  
IKr inhibitor  
INa‑L augmentation  
QTc interval  
CrCl (creatinine clearance)  
Electrolyte balance  
Magnesium  
Potassium  
Creatinine  
Dronedarone  
Hepatic toxicity (dronedarone)  
Ibutilide  
QT prolongation  
Non‑sustained ventricular tachycardia  
Ventricular tachycardia  
Continuous electrocardiographic monitoring  
12‑lead ECG  
Serum magnesium  
Serum potassium  
Renal function  
Antiarrhythmic agents  
Drug‑induced lung toxicity

Page 83 Extracted Terms:
- Atrial fibrillation  
- Left ventricular ejection fraction (LVEF)  
- Ventricular tachycardia (VT)  
- Torsades de pointes (TdP)  
- Hypokalemia  
- Hypomagnesemia  
- Ibutilide  
- Procainamide  
- Sotalol  
- Dofetilide  
- Dronedarone  
- 12‑lead electrocardiogram  
- Serum potassium  
- Serum magnesium  
- Creatinine clearance (CrCl)  
- Blood pressure (BP)  
- QTc interval  
- QRS complex / width  
- Proarrhythmia  
- Hypotension  
- Renal function  
- Drug‑induced torsades de pointes  
- Antiarrhythmic drugs  
- Upstream therapy  
- ACE inhibitors  
- Glucocorticoids  
- Electrocardiographic monitoring  
- Continuous ECG monitoring

Page 84 Extracted Terms:
**Key terms related to heart disease (as extracted from the guideline excerpt)**  

- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Rhythm control strategies  
- Catheter ablation  
- Anti‑arrhythmic drugs (AADs)  
- Symptomatic AF  
- Paroxysmal AF  
- Persistent AF  
- Progressive AF  
- New‑onset atrial arrhythmias  
- Post‑operative AF  
- Atrial arrhythmia recurrence  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure (HF)  
- Chronic kidney disease (CKD)  
- Type 2 diabetes mellitus (T2DM)  
- Sodium‑glucose cotransporter 2 inhibitors (SGLT2‑i)  
- Aldosterone antagonists (e.g., spironolactone)  
- Angiotensin‑converting enzyme (ACE) inhibitors  
- Angiotensin II receptor blockers (ARBs)  
- Statins (e.g., rosuvastatin)  
- Omega‑3 polyunsaturated fatty acids  
- Antioxidants (e.g., ascorbic acid)  
- Glucocorticoids  
- Fibrosis‑targeting therapies  
- Fibrosis reduction  
- Economic value (intermediate)  
- Quality of life (QOL)  
- Cardiovascular outcomes  
- Clinical outcomes  
- Adverse drug effects  
- Clinical and procedural success rates  
- Registry data  
- Randomized controlled trials (RCTs)  
- Meta‑analysis  

These terms capture the primary disease entities, therapeutic modalities, pharmacologic agents, patient populations, and outcome considerations discussed in the guideline passage.

Page 85 Extracted Terms:
Atrial fibrillation  
Paroxysmal atrial fibrillation  
Persistent atrial fibrillation  
Atrial flutter (AFL)  
Atrial tachyarrhythmias  
Recurrent arrhythmia / recurrence of atrial arrhythmia  
AF burden  
Catheter ablation  
Cryoballoon pulmonary vein isolation (PVI)  
Cavo‑tricuspid isthmus (CTI) ablation  
Antiarrhythmic drug therapy (AAD)  
Rhythm control  
Cardiovascular hospitalization (related to AF)  
Quality‑of‑life (QOL) in AF patients  
Cost‑effectiveness of AF treatment  
Symptom improvement in atrial fibrillation  
Antiarrhythmic drug group  
Ablation group (first‑line)  
Early aggressive invasive intervention for AF (EARLY‑AF)  
STOP AF First study (cryoballoon ablation)  
MANTRA‑AF study  
Ablation vs. antiarrhythmic drug comparison  
Recurrent atrial tachyarrhythmias after ablation  
Cryoballoon ablation of AFL  
Pulmonary vein isolation (PVI) effectiveness in AFL  
Procedural complications of ablation (2–5%)

Page 86 Extracted Terms:
**Terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Paroxysmal AF  
- Persistent AF  
- Atrial flutter (AFL)  
- Atrial tachycardia (AT)  
- Catheter ablation  
- Pulmonary vein isolation (PVI)  
- Rhythm‑control strategy  
- Anti‑arrhythmic medication  
- Heart failure (HF)  
- Left ventricular (LV) function  
- Heart‑failure with reduced ejection fraction (HFrEF)  
- Cardiovascular death  
- Ischemic stroke  
- Transient ischemic attack (TIA)  
- Acute coronary syndrome (ACS)  
- Stroke risk (CHA₂DS₂‑VASc score)  
- Intravascular complications (e.g., pulmonary vein stenosis)  
- Esophageal atrial fistula  
- Pericardial effusion  
- Vascular complications  
- Low‑voltage areas  
- Complex fractionated electrograms (CFEEs)  
- Rotors (focal drivers)  
- Infiltrative cardiomyopathy (e.g., amyloidosis)  
- Mitral stenosis  
- Mitral regurgitation  
- Cor pulmonale  
- Atrial enlargement  
- Myocardial fibrosis  
- Composite clinical outcome (cardiac death, stroke, HF hospitalization, ACS)  
- Ablation‑related adverse events  
- Atrial substrate  
- Cardiomyopathy  
- Prognostic factors (age, atrial size, fibrosis)  
- Catheter‑based intervention  
- Quality‑adjusted life year  
- Cost‑effectiveness modeling  

These terms capture the principal concepts of heart disease discussed in the guidelines excerpt.

Page 87 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal supraventricular tachycardia (SVT)  
- Pulmonary vein isolation (PVI)  
- Catheter ablation  
- Left atrial (LA) mechanics  
- Atrioesophageal fistula  
- Atrial scar  
- Atrial arrhythmia (including atrial flutter)  
- Recurrent atrial fibrillation  
- Anti‑arrhythmic drug therapy  
- Stroke (cardio‑embolic)  
- Left ventricular (LV) dysfunction  
- Stiff left atrial syndrome  
- Pulmonary vein stenosis  
- Left atrial appendage (LAA)  
- Ligament of Marshall  
- Atrial myopathy  
- Substrate modification during ablation  
- PV-to-LA reconnection  
- Post‑ablation blanking period complications  

These terms capture the key heart‑disease concepts discussed in the guideline excerpts.

Page 88 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Antiarrhythmic drug therapy  
- Anticoagulation therapy  
- Warfarin  
- Direct oral anticoagulants (DOAC)  
- Vitamin K antagonist  
- Intraprocedural intravenous anticoagulation  
- Heparin  
- Direct thrombin inhibitors  
- CHA₂DS₂‑VASc score  
- Thromboembolic events  
- Stroke  
- Periprocedural bleeding  
- Major bleeding  
- Myocardial injury  
- Vascular instrumentation  
- Cardiovascular outcomes  
- Arrhythmia burden  
- Quality of life (QOL)  
- Clinical trials  
- Observational studies  
- Randomized controlled trials  
- Complications after catheter ablation  
- Silent cerebral ischemic events  
- Periprocedural stroke risk  
- Antithrombotic therapy  
- Coagulopathy  
- Cardiac instrumentation  
- Intravascular procedure  
- Endocardial ablation  
- Heart rhythm disorder  
- Cardiac arrhythmia  
- Cardiac anticoagulation  
- Stroke risk stratification  
- Ablation procedure safety  
- Anticoagulation interruption  
- Uninterrupted warfarin therapy  
- Uninterrupted DOAC therapy  
- Minimally interrupted anticoagulation  
- Continuous anticoagulation.

Page 89 Extracted Terms:
- Atrial fibrillation (AF)  
- Catheter ablation  
- Left atrial (LA)–esophageal fistula  
- Cardiac perforation  
- Pericardial tamponade  
- Cerebrovascular accident (CVA)  
- Transient ischemic attack (TIA)  
- Pulmonary vein (PV) stenosis  
- Phrenic nerve paralysis  
- Vascular access complications  
- Myocardial injury/death (procedure‑related)  
- Pneumonia (post‑procedure)  
- CHA₂DS₂‑VASc score  
- Oral anticoagulation  
- Left atrial appendage occlusion (LAAO)  
- Anticoagulation discontinuation/continuation after ablation  
- Pacemaker implantation  
- Implantable cardioverter‑defibrillator (ICD)  
- Bradycardia  
- Atrioventricular (AV) conduction  
- AV synchrony  
- Atrial tachyarrhythmias  
- Antitachycardia pacing  
- Ventricular pacing reduction  

These are the core heart‑disease terms and concepts highlighted in the guideline excerpt.

Page 90 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial tachyarrhythmia  
- Atrial ectopy  
- Atrial pacing algorithms  
- Antitachycardia pacing (ATP) algorithms  
- Conduction system pacing  
- Ventricular pacing  
- Atrioventricular synchrony    
- Left bundle branch area pacing  
- His bundle pacing  
- Right ventricular (RV) pacing  
- Sinus node dysfunction  
- Atrioventricular (AV) block  
- PR interval  
- Reentry mechanism  
- Cardiac‑implanted electronic devices (CIED)  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Surgical ablation (atrial)  
- Hybrid epicardial‑endocardial ablation  
- Anticoagulation therapy  
- Stroke  
- Systemic embolism  
- Heart failure  
- Pacing algorithms (general)  
- Pace‑support rate setting  
- Ventricular depolarization pattern  
- Atrial arrhythmia  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- ATTEST trial  
- MINERVA study  
- MOST study  
- Meta‑analysis  
- Randomized controlled trial (RCT)  
- Retrospective analysis

Page 91 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Atrial tachycardia (AT)  
- Cardiac surgery  
- Surgical ablation  
- Cryoablation  
- Radiofrequency ablation  
- Mitral valve surgery  
- Aortic surgery  
- Tricuspid surgery  
- Coronary artery bypass grafting (CABG)  
- Pacemaker placement  
- Renal dysfunction  
- Epicardial ablation  
- Endocardial ablation  
- Hybrid procedure (closed‑chest epicardial + endocardial ablation)  
- Pulmonary vein isolation (PVI)  
- Left atrial posterior wall ablation  
- Atrial remodeling  
- Diastolic dysfunction  
- Heart failure (HF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Left ventricular systolic dysfunction  
- Total mortality  
- Stroke  
- Systemic embolism  
- Oral anticoagulation  
- Warfarin  
- Direct oral anticoagulant (DOAC)  
- Mechanical heart valve  
- Mitral stenosis  
- Atrial stunning  
- Stasis of blood flow  
- Virchow’s triad  
- Endothelial injury  
- Thrombogenic milieu  
- Major adverse events  
- Bleeding  
- Pericardial effusion

Page 92 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- Left ventricular ejection fraction (LVEF)  
- Left ventricular dysfunction / LV dysfunction  
- Arrhythmia‑induced cardiomyopathy  
- AF‑induced cardiomyopathy  
- AF‑mediated cardiomyopathy  
- Ventricular remodeling  
- Bradycardia / rate control  
- Digoxin (rate‑control agent)  
- Amiodarone (rate‑control agent)  
- Anticoagulation therapy  
- Catheter ablation (AF rhythm‑control therapy)  
- Atrioventricular nodal ablation (AVNA)  
- Biventricular pacing (cardiac resynchronization therapy)  
- Conduction‑system pacing  
  - His bundle pacing  
  - Left bundle branch area pacing  
- Implantable cardioverter‑defibrillator (ICD) – shock risk  
- New‑onset heart failure (NYHA classes III–IV)  
- Cardioversion (pharmacologic and electrical)  
- Atrial arrhythmia burden  
- Stroke risk  
- Mortality (HF‑related)  
- Hospitalization for worsening heart failure  
- Quality of life (QOL) measures in HF/AF patients

These terms capture the central concepts of cardiovascular disease addressed in the guideline excerpts.

Page 93 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Heart failure with preserved ejection fraction (HFpEF)  
- New‑York Heart Association (NYHA) class  
- Left ventricular ejection fraction (LVEF)  
- Catheter ablation (for AF)  
- Antiarrhythmic drugs  
- Digoxin  
- Carvedilol  
- Bisoprolol  
- Amiodarone (intravenous)  
- Diltiazem (intravenous)  
- Beta‑blockers (intravenous)  
- Atrioventricular node ablation (AVNA)  
- Pacemaker implantation (right‑ventricular pacing, biventricular pacing)  
- Cardiac resynchronization therapy (CRT)  
- Mortality rate  
- Hospitalization rate (HF hospitalizations)  
- Quality of life (QOL)  
- Natriuretic peptide levels  
- Ventricular rate control  
- Hypotension (as a side‑effect of rhythm‑control drugs)  
- Thromboembolism risk (in AF)

Page 94 Extracted Terms:
- AAD (antiarrhythmic drug)  
- AATAC (Ablation vs Amiodarone for Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure and an Implanted ICD/CRTD)  
- AF (atrial fibrillation)  
- AMICA (Atrial Fibrillation Management in Congestive Heart Failure With Ablation)  
- ARC‑HF (A Randomised Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure)  
- BNP (brain natriuretic peptide)  
- CABANA (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation)  
- CAMERA MRI (Catheter Ablation versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction-an MRI‑Guided Multi‑centre Randomised Controlled Trial)  
- CAMTAF (Catheter Ablation Versus Medical Treatment of AF in Heart Failure)  
- CASTLE‑AF (Catheter Ablation versus Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation)  
- CHF (congestive heart failure)  
- CM (cardiomyopathy)  
- CMR (cardiac magnetic resonance)  
- HF (heart failure)  
- HFpEF (heart failure with preserved ejection fraction)  
- ICD (implantable cardioverter‑defibrillator)  
- LVEF (left ventricular ejection fraction)  
- MACE (major adverse cardiovascular events)  
- NSR (normal sinus rhythm)  
- NYHA (New York Heart Association)  
- PAF (paroxysmal atrial fibrillation)  
- QOL (quality of life)  
- RAFT‑AF (Rhythm Control–Catheter Ablation With or Without Anti‑arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio‑ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation)  
- RF (radiofrequency)  
- VO₂ max (maximal oxygen consumption)  
- 6MWT (6‑minute walk test)  
- pro‑BNP (N‑terminal pro‑brain natriuretic peptide)  
- PAF or persistent AF  
- NYHA class II or III heart failure  
- Composite of death and hospitalization  
- Composite of MACE  
- Normal sinus rhythm (NSR)  
- Anti‑arrhythmic drug (AAD) therapy  
- Catheter ablation  
- Radiofrequency ablation  
- Catheter ablation versus rate control  
- Catheter ablation versus anti‑arrhythmic drug therapy  
- Anti‑arrhythmic drug versus amiodarone  
- Left ventricular dysfunction  
- Systolic dysfunction  
- Cardiac magnetic resonance imaging (CMR)  
- Brain natriuretic peptide (BNP)  
- Heart‑failure‑related mortality  
- Hospitalization for heart failure  
- Quality‑of‑life improvement  
- Six‑minute walk distance improvement  
- Peak VO₂ improvement.

Page 95 Extracted Terms:
- Atrial fibrillation  
- Atrioventricular  
- Cardiomyopathy  
- Cardiac magnetic resonance  
- Guideline‑directed medical therapy  
- Heart failure  
- Heart failure with preserved ejection fraction  
- Heart failure with reduced ejection fraction  
- Left ventricular ejection fraction  
- Nondihydropyridine calcium channel blocker  
- New York Heart Association  


Page 96 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Cardiomyopathy (AF‑induced, arrhythmia‑induced)  
- Biventricular pacing  
- Cardiac resynchronization therapy (CRT)  
- Conduction system pacing  
- His bundle pacing  
- Left bundle branch area pacing  
- Atrioventricular node ablation (AVNA)  
- Implantable cardioverter‑defibrillator (ICD)  
- Left ventricular ejection fraction (LVEF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- New York Heart Association (NYHA) class  
- Ventricular rate  
- Rate control strategy  
- Rhythm control strategy  
- Antiarrhythmic therapy (e.g., metoprolol)  
- Metoprolol (dose escalation)  
- Pacing thresholds  
- Pacing percentage (≥ 98 % biventricular pacing)  
- All‑cause mortality  
- Cardiovascular mortality  
- Holter monitor  
- Event monitor  
- Mobile telemetry  
- Implantable loop recorder  
- Wearable devices (e.g., smart watches)  
- 6‑minute walk test (used for target heart‑rate assessment)  
- Clinical trials (e.g., AF‑CHF, RACE II, AF‑CRT)  
- Systematic review and meta‑analysis  
- Observational studies/trials  
- Remote monitoring data  
- Pacing strategies (RV pacing, CRT pacing)  
- ICD shocks (appropriate/inappropriate)  
- Hospitalizations (all‑cause)  

These terms encompass the key concepts related to heart disease—conditions, clinical endpoints, therapeutic devices, pacing strategies, biomarkers, and monitoring tools—presented in the provided guidelines text.

Page 97 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Heart failure with reduced ejection fraction (HFrEF)  
- Non‑ischemic cardiomyopathy  
- Ejection fraction (EF)  
- Left‑ventricular ejection fraction (LVEF)  
- Pulmonary congestion  
- New‑York Heart Association (NYHA) class (I–IV)  
- Conduction system pacing  
- Right‑ventricular/biventricular pacing (RV/BiVP)  
- Diltiazem (nondihydropyridine calcium‑channel blocker)  
- Verapamil (nondihydropyridine calcium‑channel blocker)  
- Inotropic support  
- Dronedarone (anti‑arrhythmic)  
- Cardiovascular mortality  
- Cardiac death  
- Non‑fatal reinfarction  
- Late heart failure  
- Arrhythmic death  
- Genetic testing for cardiomyopathy/ion‑channel disorders  
- Inherited ion‑channel disorders  
- Cardiomyopathy surveillance  
- Reentrant supraventricular tachyarrhythmias (SVTs)  
- Electrophysiological study (EPS)  
- Catheter ablation  
- Acute kidney injury  
- Myocardial infarction (MI)  
- Post‑acute MI complications  
- Hospitalization due to heart failure  
- Recurrent atrial arrhythmias (AF or SVT)

Page 98 Extracted Terms:
- Atrial fibrillation (AF)  
- Slow pathway ablation  
- Pulmonary vein isolation (PVI)  
- Catheter ablation  
- Cardiomyopathy-related genes  
- Ion channelopathy genes  
- Exercise-induced atrial myopathy  
- Exercise-related inflammation  
- Cardiopulmonary exercise stress testing  
- Metabolic equivalents (METs)  
- Obesity (BMI ≥ 30 kg/m²)  
- Class III obesity (BMI ≥ 40 kg/m²)  
- Body mass index (BMI)  
- Left atrial (LA) dilatation  
- Hyperlipidemia  
- Hypertension  
- Heart failure (HF)  
- Sleep apnea  
- Weight loss (primary and secondary prevention of AF)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Bariatric surgery  
- Anticoagulation considerations  
- Anticoagulation risk reduction  
- Paroxysmal AF  
- Persistent AF  
- Permanent AF  
- AF recurrence  
- Stroke risk  
- Anticoagulation drug absorption  
- Framingham Study risk metrics  
- Echocardiogram (normal vs abnormal)  
- QOL (quality of life) improvement  
- Exercise capacity preservation  
- Metabolic equivalent-hours per week  
- Exercise volume (high-volume endurance athlete)  
- Age of AF onset (<45, <66 years)  
- Athlete population  
- AF prognosis in obesity  
- BMI‑adjusted hazard ratios (HR) for AF  
- AF burden  
- Obesity‑mediated structural atrial changes  
- Epicardial fat  
- Abdominal fat  
- Cardiopulmonary exercise treadmill testing  
- Long‑term follow‑up studies (10‑year, 3‑year)  

Page 99 Extracted Terms:
- Atrial fibrillation (AF)  
- Class III obesity (BMI ≥ 40 kg/m²)  
- Body mass index (BMI)  
- Direct oral anticoagulants (DOAC)  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Dabigatran  
- Warfarin  
- Stroke‑risk prevention in AF  
- Ischemic stroke  
- Systemic embolism  
- Major bleeding  
- Bariatric surgery  
- Drug peak trough levels after bariatric surgery  
- Oral anticoagulation therapy  
- Percutaneous left atrial appendage occlusion (LAAO)  
- Surgical left atrial appendage exclusion/excision  
- Surgical ablation in AF  
- Valvular heart disease (VHD)  
- Cerebrovascular events in VHD  
- Accessory pathways (AP)  
- Wolff–Parkinson–White syndrome (WPW)  
- Pre‑excited atrial fibrillation  
- Preexcitation syndromes  
- Intravenous ibutilide  
- Intravenous procainamide  
- Verapamil (AV‑nodal blocker)  
- Diltiazem (AV‑nodal blocker)  
- Amiodarone (antiarrhythmic)  
- Digoxin (antiarrhythmic)  
- Adenosine (antiarrhythmic)  
- Beta‑blockers (AV‑nodal blocker)  
- Ventricular fibrillation (VF)  
- Sudden cardiac death  
- Electrical cardioversion  
- Catheter ablation of accessory pathways  
- Anticoagulation‑associated bleeding risk  
- Thromboembolism prevention  
- Lipid‑risk scoring  

*(List contains key terms related to heart disease drawn from the guideline excerpt.)*

Page 100 Extracted Terms:
- Preexcited atrial fibrillation (AF)  
- Ventricular fibrillation (VF)  
- Electrical cardioversion  
- Pathway (ablation)  
- Atrial fibrillation (AF)  
- Atrial tissue refractory period  
- Ibutilide  
- Procainamide  
- Atrioventricular (AV) nodal block  
- AV‑nodal blocking agents  
- Amiodarone  
- Verapamil  
- Hypertrophic cardiomyopathy (HCM)  
- AHA/ACC guideline for hypertrophic cardiomyopathy  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Antiarrhythmic drugs  
- Catheter ablation  
- Adult congenital heart disease (ACHD)  
- Hemodynamic sequelae  
- Electrophysiological procedures  
- Pulmonary vein isolation (PVI)  
- Atriotomy scars  
- Cavotricuspid isthmus (CTI)  
- Fontan circulation  
- Anticoagulation  
- Thromboembolic events  
- Risk scores (e.g., CHA₂DS₂‑VASc, CHADS‑VASc)  
- Stroke  
- Atrial arrhythmias  
- Hemodynamic instability  
- Rapid ventricular response  
- Reentrant arrhythmia  
- Atrial rhythm‑control strategy  

Page 101 Extracted Terms:
- Atrial Fibrillation (AF)  
- Congenital Heart Disease (CHD)  
- Adult Congenital Heart Disease (ACHD)  
- Simple, Moderate, and Complex forms of CHD  
- Sinus Node Dysfunction  
- Atrioventricular Block  
- Ventricular Dysfunction (subpulmonary & systemic)  
- Right Atrial (RA) Dilation  
- Fontan Physiology  
- Low‑Flow States  
- Thromboembolic Prophylaxis  
- CHA₂DS₂‑VASc Score  
- Direct Oral Anticoagulants (DOACs)  
- Amiodarone (antiarrhythmic)  
- Dofetilide (antiarrhythmic)  
- Dronedarone (antiarrhythmic)  
- Class I Antiarrhythmic Drugs  
- Pulmonary Vein Isolation (PVI)  
- Cryoballoon Ablation  
- Transseptal Puncture  
- CTI (cave‑to‑tricuspid isthmus) Ablation  
- Atriotomy Scars  
- Left Superior Vena Cava  
- Right Atrial (RA) pathology in repaired complex ACHD  
- Stroke  
- Heart Failure (HF)  
- Survival Outcomes in ACHD  
- Periprocedural Care  
- Ancillary Imaging in ACHD  
- Proarrhythmic Effects  
- Thyrotoxicosis (amiodarone‑induced)  
- BMI <21 kg/m² (risk factor for thyrotoxicosis)  
- Cyanotic Lesions  
- Blind‑ending Cardiac Chambers  
- Cerebrovascular Accidents (CVA)  
- Hemodynamic Sequelae of Childhood Repair  
- Electrophysiologic Procedures in ACHD  



Page 102 Extracted Terms:
**Key heart‑disease related terms extracted from the guideline text**

- Atrial fibrillation (AF)  
- New‑onset postoperative AF  
- Postoperative atrial fibrillation  
- Cardiac surgery  
- Coronary artery bypass graft (CABG)  
- Aortic valve surgery  
- Ascending aortic aneurysm surgery  
- Posterior left pericardiotomy  
- Beta‑blockers (pre‑operative prophylaxis)  
- Amiodarone (pre‑operative prophylaxis)  
- Colchicine (prophylaxis)  
- Rate control (target <100 bpm)  
- Rhythm control  
- Non‑dihydropyridine calcium channel blockers  
- Direct current cardioversion  
- Antiarrhythmic drug therapy  
- Anticoagulation (post‑operative management)  
- Left atrial appendage thrombus  
- Stroke risk  
- Late mortality  
- Hemodynamic stability  
- Heart rate  
- Post‑operative complications  
- Antiarrhythmic medication  
- Clinical trials (RCT, meta‑analysis)  
- Incidence of AF  
- Thrombosis risk  
- Bleeding risk  
- Reevaluation of long‑term anticoagulation  

These terms capture the primary clinical concepts, interventions, and outcomes relevant to heart disease discussed in the guideline excerpt.

Page 103 Extracted Terms:
- Atrial fibrillation (AF)  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Beta blockers  
- Calcium channel blockers  
- Amiodarone  
- Cardioversion  
- Anticoagulation / anticoagulants  
- Thromboembolic events  
- Stroke (high‑risk for stroke)  
- Left atrial appendage (LAA) imaging  
- Post‑operative AF  
- Hemodynamically stable patient  
- Hemodynamically poorly tolerated AF  
- Cardiac surgery  
- Heart rate (HR)  
- Mortality rate  
- Colchicine (anti‑inflammatory)  
- Post‑discharge follow‑up  
- Clinical guideline statements  

Page 104 Extracted Terms:
- Atrial fibrillation (AF)  
- Acute atrial fibrillation (acute AF)  
- AF recurrence  
- Heart failure (HF)  
- Stroke  
- Mortality  
- Anticoagulation  
- Oral anticoagulant (OAC)  
- Parenteral anticoagulation  
- Thromboembolism / thromboembolic risk  
- Critical illness  
- Sepsis  
- Non‑cardiac surgery  
- Cardiac surgery  
- Rhythm monitoring  
- Outpatient follow‑up  
- Rhythm control strategy  
- Rate control strategy  
- Hemodynamics  
- AF surveillance  
- Risk stratification  
- CHA₂DS₂‑VASc score  
- Bleeding risk  
- In‑hospital stay  
- Long‑term risk  
- Paroxysmal AF  
- Persistent AF

Page 105 Extracted Terms:
- Atrial fibrillation (AF)  
- Acute atrial fibrillation (acute AF)  
- Recurrent atrial fibrillation (recurrent AF)  
- Oral anticoagulants (OACs)  
- Anticoagulation  
- Ischemic stroke  
- Bleeding  
- Cardiac surgery  
- Non‑cardiothoracic surgery  
- Infection (as a precipitant for AF)  
- Precipitants (of AF)  
- Critical illness (in the context of AF)  
- Unadjusted cumulative risk of AF recurrence  
- Kaplan‑Meier method (used for AF recurrence analysis)  
- Cardiothoracic (CT)  
- American Heart Association (reference and source of figures)

Page 106 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter (AFL)  
- Hyperthyroidism  
- Anticoagulation therapy  
- Stroke risk / thromboembolic risk  
- Antithrombotic therapy  
- Cardioselective beta‑blockers  
- Non‑selective beta‑blockers  
- Pulmonary hypertension (PH)  
- Pulmonary vascular disease  
- Rhythm‑control strategy  
- Functional status  
- Survival  
- Pulmonary embolism (PE)  
- Myocardial infarction (MI)  
- Heart failure (HF)  
- Coronary artery disease (CAD)  
- Beta‑2 agonists  
- Propranolol  
- Euthyroid state  
- Antithyroid treatment  
- Warfarin  
- Apixaban

Page 107 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial arrhythmias  
- Atrial flutter (AFL)  
- Pulmonary hypertension (PH)  
- Pulmonary vascular disease (PHPVD)  
- WHO pulmonary hypertension groups 1, 3, 4  
- Right atrial contraction  
- Sinus rhythm  
- Cardioversion  
- Direct‑current cardioversion (DCCV)  
- Antiarrhythmic drug therapy  
- Catheter ablation (including left atrial ablation)  
- Transseptal puncture  
- Left‑sided obstructive lesions  
- Congenital heart disease (CHD)  
- Valvular heart disease (VHD)  
- Anticoagulation (including DOACs)  
- Stroke risk (as a cardiac complication)  
- Hemodynamic parameters (e.g., pulmonary vascular resistance, left heart filling pressures)  
- Pregnant individuals with heart disease  
- Hormonal influences on cardiac rhythm (e.g., elevated progesterone)  
- Hypertensive disorders of pregnancy  
- Beta blockers (including cardioselective agents)  
- Digoxin  

---

Page 108 Extracted Terms:
- Atrial fibrillation (AF)  
- Stroke risk in AF  
- Anticoagulation strategies  
- Warfarin (vitamin K antagonist)  
- Low‑molecular‑weight heparin (LMWH)  
- Unfractionated heparin (UFH)  
- Direct oral anticoagulants (DOACs)  
- Valvular heart disease (VHD)  
- Mitral stenosis  
- Beta‑blockers (e.g., propranolol, metoprolol)  
- Digoxin  
- QTc prolongation  
- Proarrhythmia  
- Bleeding risk  
- Thromboembolism  
- Heart failure (HF)  
- Cardio‑oncology  
- Cancer‑associated atrial fibrillation  
- Ibrutinib (Bruton’s tyrosine kinase inhibitor)  
- Systemic inflammation  
- Hypertension  
- Obesity  
- Thoracic radiation therapy  
- Thoracic surgery  
- Pregnancy‑related anticoagulation  
- Intravenous heparin  
- International Normalized Ratio (INR)  
- Delivery planning in anticoagulated patients  
- Anticoagulation during pregnancy (first, second, third trimesters)

Page 109 Extracted Terms:
- Atrial fibrillation (AF)  
- Heart failure (HF)  
- Myocardial infarction (MI)  
- Hypertension  
- Stroke  
- Cardiovascular disease (CVD)  
- Peripheral cardiovascular complications (e.g., perioperative AF)  
- Guideline‑directed medical therapy (GDMT)  
- Oral anticoagulants (OACs)  
- Anti‑arrhythmic agents  
- Beta‑blockers (rate‑control agents)  
- QTc prolongation / QT‑prolonging agents  
- Drug‑drug interactions between cancer therapies and anticoagulants  
- Cancer therapeutics associated with increased AF risk (e.g., anthracyclines, antimetabolites, alkylating agents, immunomodulators, tyrosine‑kinase inhibitors, VEGF inhibitors, BRAF inhibitors, CAR T‑cell therapy, monoclonal antibodies)  
- Specific antineoplastic agents highlighted as AF risk factors:  
  - Anthracyclines (doxorubicin, epirubicin, idarubicin, mitoxantrone)  
  - Antimetabolites (clofarabine, cytarabine, 5‑fluorouracil, capecitabine, gemcitabine)  
  - Alkylating agents (cyclophosphamide, melphalan)  
  - Immunomodulatory drugs (lenalidomide, interleukin‑2)  
  - Tyrosine‑kinase inhibitors (ibrutinib, acalabrutinib, zanubrutinib, ponatinib, trametinib, osimertinib, nilotinib, ribociclib)  
  - VEGF inhibitors (sorafenib)  
  - BRAF inhibitor (vemurafenib)  
  - CAR T‑cell therapies (tisagenlecleucel, axicabtagene ciloleucel)  
  - Monoclonal antibody (rituximab)

Page 110 Extracted Terms:
- Atrial fibrillation (AF)  
- Cancer therapies associated with AF  
- Cardiovascular risk factors (hypertension, diabetes)  
- Natriuretic peptides  
- Stroke / systemic embolism  
- Major bleeding  
- Direct oral anticoagulants (DOACs)  
- Warfarin (vitamin K antagonist, VKA)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Catheter ablation  
- Amiodarone (antiarrhythmic drug)  
- Rate control therapies  
- Rhythm control therapies  
- Antiarrhythmic drug dosing in CKD  
- Chronic kidney disease (CKD)  
- Kidney failure / end‑stage renal disease  
- Estimated glomerular filtration rate (eGFR)  
- Proteinuria  
- Renal dysfunction  
- Fluid balance management during radiofrequency ablation  
- Anticoagulation in CKD and AF  
- Liver disease (cirrhosis)  
- Child‑Pugh classification (A, B, C)  
- Coagulopathy / thrombocytopenia  
- International normalized ratio (INR)  
- HAS‑BLED bleeding risk score  
- High bleeding risk estimators  
- Thrombocytopenia (platelet < 50 000/µL)  
- Intracranial malignancy  
- Gastrointestinal malignancy  
- History of major bleeding  
- Severe kidney dysfunction (eGFR < 30 mL/min/1.73 m²)  
- Drug interactions (P‑glycoprotein, CYP3A4 inducers/inhibitors)  
- Antineoplastic drug interactions  
- Pulmonary embolism / inherited thrombophilia (implied by embolism context)

Page 111 Extracted Terms:
- Atrial fibrillation (AF)
- Oral anticoagulation (OAC) therapy
- Direct oral anticoagulants (DOACs)
- Vitamin K antagonists (VKAs)
- Oral factor Xa inhibitors
- Rivaroxaban
- Edoxaban
- Apixaban
- Dabigatran
- Warfarin
- Ischemic stroke
- Thromboembolism
- Intracranial hemorrhage (ICH)
- Major bleeding
- All‑cause mortality
- Composite cardiovascular events
- Liver disease
- Liver fibrosis
- Cirrhosis
- Child‑Pugh score/class (A, B, C)
- Hepatic metabolism
- Plasma concentration
- Esophageal varices
- Meta‑analysis
- Observational studies
- Clinical trials
- Post‑marketing retrospective studies
- Guideline
- Safety profile
- Efficacy data
- Risk‑factor modification
- Prevention strategies
- Rhythm management
- Disease continuum in AF
- Downstream long‑term consequences of AF

Page 112 Extracted Terms:
- Atrial fibrillation (AF)  
- Catheter ablation  
- Ablation failure  
- AF burden  
- Subclinical atrial fibrillation  
- Left atrial appendage occlusion (LAAO)  
- Stroke prevention  
- Anticoagulation therapy  
- Oral anticoagulants  
- CHA2DS2‑VASc score  
- Risk modifiers (stroke risk)  
- Risk scores  
- Cardioversion  
- Wearable heart‑monitoring devices  
- Artificial intelligence (AI) for AF management  
- Electrocardiographic‑guided anticoagulation  
- Pulmonary vein isolation (PVI)  
- Hypertension  
- Biomarkers for AF and stroke prediction  
- Periprocedural anticoagulation  
- LAA device implantation (pLAAO)  
- Electronic medical record integration for risk scoring  

Page 113 Extracted Terms:
- Atrial fibrillation (AF)  
- Sleep‑disordered breathing (SDB)  
- Anticoagulation  
- Direct oral anticoagulants (DOACs)  
- Rhythm management  
- Anti‑arrhythmic drugs  
- Catheter ablation  
- Genetic testing / consumer‑based genetic testing  
- Polygenic risk scores  
- Arrhythmia incidence  
- Gender‑affirming therapies (impact on arrhythmia)  
- Race, ethnicity, and gender/sex disparities in AF outcomes  
- Standardized outcome measures (symptom burden, quality‑of‑life)  
- Social determinants of health (SDOH) in AF  

These are the principal heart‑disease‑related terms identified in the guideline text.

Page 114 Extracted Terms:
- Atrial fibrillation  
- Hypertrophic cardiomyopathy  
- Valvular heart disease  
- Coronary artery revascularization  
- Chest pain  
- Stroke (in relation to cardiovascular disease)  
- Heart failure  
- Congenital heart disease  
- Arrhythmias during pregnancy  
- Cardiovascular disease / heart disease  
- Cardiovascular disease and stroke statistics  
- Global burden of disease (cardiovascular focus)  
- Incidence (of cardiovascular conditions)  
- Prevalence (of cardiovascular conditions)  
- Mortality (cardiovascular)  
- Risk factors (for cardiovascular disease)  
- Healthcare utilization (related to cardiovascular conditions)  
- Cost/value methodology (in cardiovascular guideline development)  
- Clinical practice guidelines (ACC/AHA, ESC, EHRA, EACTS)  
- ACC/AHA joint committees (e.g., on heart failure, valvular disease)  
- ESC guidelines for atrial fibrillation  
- Canadian Cardiovascular Society guidelines on atrial fibrillation  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Heart Rhythm Society (HRS)  
- European Heart Rhythm Association (EHRA)  
- European Association for Cardio‑Thoracic Surgery (EACTS)

Page 115 Extracted Terms:
- Atrial fibrillation  
- Cardiovascular disease  
- Myocardial infarction  
- Heart failure  
- Stroke / cerebrovascular disease  
- Hypertension  
- Arrhythmia  
- Obesity  
- Body mass index (BMI)  
- Weight loss / weight management  
- Bariatric surgery  
- Exercise / physical activity  
- Aerobic interval training  
- Cardio‑respiratory fitness  
- Smoking / tobacco use  
- Alcohol consumption  
- Renal disease / kidney dysfunction  
- Renal denervation  
- Catheter ablation  
- Ablation outcomes  
- Aldosterone pathway blockade  
- Blood pressure control  
- Cardiometabolic risk factors  
- Mortality  
- Morbidity

Page 116 Extracted Terms:
- Atrial fibrillation  
- Blood pressure (systolic & diastolic)  
- Resting heart rate  
- Diabetes mellitus  
- Heart failure (congestive, reduced EF, preserved EF)  
- Valvular heart disease  
- Cardiac surgery (open‑heart, valve replacement, coronary bypass)  
- β‑blockers (pre‑operative, postoperative)  
- Amiodarone (rate‑ and rhythm‑control, prophylaxis)  
- Arrhythmia (post‑operative, post‑cardioversion)  
- Revascularization (PCI, CABG)  
- Valve replacement / repair  
- Posterior left pericardiotomy (atrial fibrillation prevention)  
- Post‑operative atrial fibrillation (after cardiac surgery)  
- Chronic kidney disease (CKD)  
- Obstructive sleep apnea (OSA)  
- Continuous positive airway pressure (CPAP) therapy  
- Thyroid dysfunction / thyroid‑stimulating hormone (TSH)  
- Stroke (incident, ischemic, hemorrhagic)  
- Sepsis / severe sepsis (hospitalized patients)  
- PR interval / first‑degree heart block  
- Left ventricular hypertrophy (LVH)  
- B‑type natriuretic peptide (BNP / NT‑proBNP)  
- C‑reactive protein (CRP)  
- Lipoprotein(a)  
- Echocardiographic predictors (non‑rheumatic AF, LV mass, atrial size)  
- Left atrial functional measures (strain, volume)  
- Cardiovascular risk scores (Framingham, CHARGE‑AF)  
- Mendelian randomization studies (genetic determinants)  
- Meta‑analysis / systematic review (methodology in cardiology)

Page 117 Extracted Terms:
**Key Heart‑Disease Terms Extracted**

- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Left atrial size reduction  
- Radiofrequency ablation  
- Pulmonary veins  
- Mitral valve surgery  
- Atrial myopathy  
- Electrical remodeling  
- Inward rectifier potassium currents (I<sub>KA</sub>)  
- Connexin40 (Cx40)  
- Connexin43 (Cx43)  
- Calcium signaling  
- Ca<sup>2+</sup>/calmodulin‑dependent protein kinase II (CaMKII)  
- Inflammation (e.g., IL‑6)  
- Myeloperoxidase activity  
- Endocardial ablation  
- Ectopic atrial beats  
- Atrial ectopy  
- Conduction pathways (left‑to‑right atrial)  
- Left‑to‑right atrial K<sup>+</sup> gradient  
- Atypical atrial arrhythmias  
- Paroxysmal atrial fibrillation  
- Chronic atrial fibrillation  
- Atrial remodeling (structural & functional)  
- Atrial cardiomyopathy  
- Pulmonary vein isolation  
- Electro‑gram frequency analysis  
- Arrhythmogenic substrate  
- Sympathetic tone / mechanical stretch interaction  
- Sodium/calcium exchanger (NCX) dysfunction  
- Sarcoplasmic reticulum Ca<sup>2+</sup> leak  
- Interstitial fibrosis  
- Ventricular dysfunction (mentioned in related contexts)  

These terms summarize the most frequently referenced heart‑disease concepts, mechanisms, and interventions within the provided guideline excerpts.

Page 118 Extracted Terms:
**Key terms related to heart disease extracted from the text**

- Atrial fibrillation (AF)  
- Atrial arrhythmias / atrial arrhythmogenesis  
- Atrial remodeling  
- Sympathetic hyperinnervation  
- Parasympathetic nerve remodeling  
- Autonomic nervous system (ANS) dysregulation  
- Sympathetic and parasympathetic neuron activity  
- JNK2 signaling  
- CaMKII signaling  
- SERCA2 function / enhancer  
- Calcium handling / Ca²⁺ release and leak  
- Oxidative stress  
- Inflammatory mechanisms (e.g., CRP elevation, NLRP3 inflammasome)  
- Hypertension (immunology and neurohumoral effects)  
- Thrombogenesis (Virchow’s triad, clot formation)  
- Cardiac surgery–related postoperative arrhythmias  
- Pulmonary vein isolation (PVI)  
- Catheter ablation for AF  
- Oral anticoagulation therapy  
- Heart failure (congestive)  
- Socioeconomic status (SES) and health inequities  
- Racial and ethnic disparities in AF management  
- Sex/gender differences in AF treatment and outcomes  
- Social determinants of health (SDOH) interventions  
- Genomic/locus identification for AF (e.g., KCNQ1, KCNH2, GATA4, MYL3, etc.)  
- Genome‑wide association studies (GWAS) for AF risk  
- Rare genetic variants in cardiomyopathy and arrhythmia genes  
- Polygenic and monogenic contributions to AF risk  
- Hospital admission outcomes for AF/flutter  
- National registries and cohort studies (e.g., AF‑RISK, PINNACLE, CABANA)  
- Cardiovascular outcome metrics (stroke, mortality, complications)  
- Risk stratification (e.g., CHA₂DS₂‑VASc, HAS‑BLED)  
- Rhythm control strategies (pharmacologic, ablation, electrical cardioversion)  
- Rate control strategies  
- Neurohumoral and hemodynamic effects of lower body negative pressure  
- Multimodal pharmacologic therapy (e.g., beta‑blockers, calcium channel blockers, antiarrhythmic drugs)  
- Atrial fibrillation burden (inspiratory, rapid atrial pacing, atrial pacing models)  
- Cardiac autonomic afferent dysregulation  
- Autonomic nerve sprouting  
- Regional cardiac autonomic remodeling  
- Structural remodeling of the left atrium  
- Clinical evidence of autonomic dysfunction due to AF  
- Atrial fibrillation progression risk factors  
- Health equity initiatives and policy actions (e.g., rural health advisories, primary‑care recommendations)  
- Clinical guidelines and systematic reviews for AF management.

Page 119 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Stroke prevention  
- Anticoagulation therapy  
- Direct oral anticoagulants (DOACs)  
- Rhythm‑control therapy  
- Catheter ablation  
- Shared decision‑making  
- Risk stratification  
- Population screening  
- Community risk models  
- CHARGE‑AF score  
- C2HEST score  
- HATCH score  
- Early rhythm‑control  
- Mobile health devices  
- Wearable devices  
- Smartwatch monitoring  
- Electrocardiogram (ECG)  
- Handheld ECG device  
- Myocardial perfusion imaging  
- Coronary artery disease  
- Pulmonary embolism  
- Hyperthyroidism  
- Chronic kidney disease (CKD)  
- Non‑alcoholic fatty liver disease (NAFLD)  
- Left atrial strain  
- Left atrial volume  
- Tissue Doppler echocardiography  
- Cardiac amyloidosis  
- Myocardial function assessment  
- Arrhythmia management  
- Catheter ablation vs. medical therapy comparison  
- Stroke risk stratification (e.g., CHA₂DS₂‑VASc)  
- Anticoagulation prescription fills  
- Treatment adherence  
- Socioeconomic and racial disparities  
- Patient decision aids  
- Health literacy  
- AI‑guided atrial fibrillation screening  
- Diagnostic accuracy of ambulatory devices  
- Diagnostic accuracy of smart gadgets/wearables  
- Diagnostic accuracy of handheld ECGs  
- Screening for new‑onset atrial fibrillation  
- Left atrium and left atrial appendage anatomy (stroke implications)  
- Coronary artery disease screening in atrial fibrillation patients  

Page 120 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Arrhythmia  
- Stroke  
- Transient ischemic attack (TIA)  
- Ischemic stroke  
- Device‑detected atrial high‑rate episodes  
- Stroke risk  
- Cardiac rhythm monitoring  
- Electrocardiogram (ECG)  
- Implantable loop recorder  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac pacemaker  
- Holter monitor  
- Smartwatch  
- Photoplethysmography  
- Smartphone ECG  
- Mobile electrocardiogram  
- Catheter ablation  
- Rhythm control  
- Anticoagulation  
- Blood pressure  
- Body mass index (BMI)  
- Physical activity  
- Exercise  
- Cardiovascular fitness  
- Resting heart rate  
- Smoking / tobacco use  
- Alcohol consumption (including binge drinking / holiday heart syndrome)  
- Diabetes mellitus / blood glucose  
- Intensive blood‑pressure lowering  
- Genetic risk  
- Genome‑wide association study (GWAS)  
- Life Simple 7  
- CHARGE‑AF risk model  
- Atherosclerosis Risk in Communities (ARIC) study  
- REGARDS study  
- ACC/AHA cardiovascular disease prevention guidelines  
- Cardiac biomarkers  
- Stroke/TIA recurrence  
- Wearable technology  
- Long‑term continuous monitoring  
- Cardiovascular disease (CVD)  
- Risk factor prediction models  
- Competing cardiovascular risk factors  

Page 121 Extracted Terms:
Atrial fibrillation  
Cardiovascular disease (CVD)  
Heart failure  
Stroke  
Cardiac arrhythmia  
Obesity  
Weight loss  
Cardiometabolic risk factors  
Diabetes mellitus  
Glycated hemoglobin (HbA1c)  
Cardiac rehabilitation  
Exercise training  
Aerobic interval training  
Cardiac exercise  
Catheter ablation  
Smoking cessation  
Physical fitness  
Exercise‑based cardiac rehabilitation  
Risk factor modification  
Electrophysiological and structural remodeling of the atria

Page 122 Extracted Terms:
Atrial fibrillation  
Paroxysmal atrial fibrillation  
Atrial tachyarrhythmia  
Atrial fibrillation recurrence  
Post‑operative atrial fibrillation  
Cardiac surgery (heart valve surgery, cardiopulmonary bypass)  
Coronary artery bypass grafting  
Heart failure (including chronic heart failure)  
Diabetes mellitus  
Hypertension  
Aldosterone pathway blockade  
Renal denervation  
Catheter ablation (electrical cardioversion, ablation)  
Weight management / weight loss  
Smoking (cigarette smoking)  
Alcohol consumption (alcohol abstinence, acute alcohol intake)  
Caffeine consumption (coffee, energy drinks)  
Dietary supplementation  
Omega‑3 fatty acids (n‑3 polyunsaturated fatty acids, marine omega‑3)  
Vitamin D supplementation  
Vitamin C supplementation  
Fish oil supplementation  
Nutritional risk factors (low‑carbohydrate diet, caloric reduction)  
Inflammation and oxidative stress  
Stroke risk linked to atrial fibrillation  
Anticoagulation control (warfarin, non‑vitamin K antagonist oral anticoagulants)

Page 123 Extracted Terms:
- Atrial fibrillation (AF)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Non‑valvular atrial fibrillation  
- Atrial fibrillation recurrence  
- Rhythm control strategy  
- Rate control strategy  
- Catheter ablation  
- Pulmonary vein isolation  
- Electrical cardioversion  
- Long‑term maintenance of sinus rhythm  
- Anticoagulated patients  
- Anticoagulant therapy (warfarin, DOACs)  
- Stroke prevention in AF  
- Systemic embolism  
- Cardiovascular events (CVE)  
- Hypertension  
- Blood‑pressure‑lowering treatment  
- Aggressive blood‑pressure control  
- Mean arterial pressure targets  
- Weight management/weight reduction  
- Cardiometabolic risk factors  
- Lifestyle modification  
- Alcohol abstinence/alcohol control  
- Mobile health (mHealth) technologies  
- Clinical decision support systems (CDSS)  
- Nurse‑led care programs  
- Integrated chronic care models  
- Cardiac rehabilitation programs  
- Sleep‑disordered breathing (SDB)  
- Obstructive sleep apnea (OSA)  
- Central sleep apnea  
- Continuous positive airway pressure (CPAP) therapy  
- Apnea‑hypopnea syndrome  
- Sleep duration (short sleep)  
- Sleep apnea severity  
- 2MACE score (cardiovascular risk stratification)  
- RACE 3 trial (targeted therapy for underlying conditions)  
- ARISTOTLE trial (apixaban efficacy)  
- ROCKET AF study (predictors of mortality)  
- SMAC‑AF trial (aggressive BP control in ablation)  
- VARIOSA‑AF study (sleep apnea variability)  
- RESPIRE study (sleep apnea incidence in pacemakers)  
- ALL‑IN cluster randomized trial (integrated AF management)  
- SAFETY trial (AF‑specific management strategy)  
- IMPACT‑AF program (computerized decision support for AF care).

Page 124 Extracted Terms:
- Atrial fibrillation  
- Stroke  
- Thromboembolism  
- Ischemic stroke  
- Systemic embolism  
- Oral anticoagulants  
- Warfarin  
- Direct oral anticoagulants (DOACs)  
- Apixaban  
- Dabigatran  
- Rivaroxaban  
- Edoxaban  
- Clopidogrel  
- Aspirin  
- Antithrombotic therapy  
- HAS‑BLED score  
- CHA2DS2‑VASc score  
- ATRIA stroke‑risk score  
- CHADS2 score  
- GARFIELD‑AF risk score  
- Hemorrhage / major bleeding  
- Bleeding‑risk assessment  
- Stroke‑risk assessment  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Sustained atrial fibrillation  
- ARISTOTLE trial  
- ENGAGE AF‑TIMI 48 trial  
- ROCKET‑AF trial  
- Net clinical benefit  
- Cardiovascular risk markers

Page 125 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Stroke  
- Cryptogenic stroke  
- Embolic stroke of undetermined source  
- Ischemic stroke  
- Transient ischemic attack  
- Thromboembolism  
- Anticoagulants  
- Antithrombotic therapy  
- Direct oral anticoagulants (DOACs)  
- Rivaroxaban  
- Apixaban  
- Dabigatran  
- Edoxaban  
- Warfarin  
- Low‑dose aspirin  
- Direct factor Xa inhibitors  
- Direct thrombin inhibitors  
- Anticoagulant dosing (under‑ dosing, over‑ dosing, label‑adherent dosing)  
- Drug‑drug interactions with DOACs  
- Enzyme‑inducing antiseizure medications  
- Vitamin‑K guided anticoagulation strategy  
- Implantable loop recorder  
- Holter‑based electrocardiographic monitoring  
- Subclinical atrial fibrillation  
- Device‑detected atrial high‑rate episodes  
- Stroke risk scores  
- CHA2DS2‑VASc score  
- CHADS2 score  
- ATRIA score  
- Hypertrophic cardiomyopathy  
- Valvular atrial fibrillation  
- Nonvalvular atrial fibrillation  
- Left ventricular thrombus  
- Pulmonary hypertension  
- Stroke prevention after cryptogenic stroke  
- Cardiovascular outcomes research  
- FDA adverse event reporting in anticoagulation therapy  

Page 126 Extracted Terms:
Atrial fibrillation  
Device‑detected atrial fibrillation  
Subclinical atrial fibrillation  
Atrial tachyarrhythmia  
Atrial high‑rate episodes  
Left atrial appendage (LAA)  
Left atrial appendage closure  
Left atrial appendage occlusion  
Left atrial appendage exclusion  
LAAOS study  
ASAP study  
ASAP‑TOO trial  
PROTECT AF trial  
PREVAIL trial  
PINNACLE FLX trial  
EWOLUTION trial  
Watchman device  
AtriClip device  
Anticoagulation  
Warfarin  
Direct oral anticoagulants (DOACs)  
Rivaroxaban  
Dabigatran  
Idarucizumab  
Prothrombin complex concentrate  
Activated prothrombin concentrate  
Bleeding  
Active bleeding on anticoagulant therapy  
Antithrombotic therapy  
Stroke  
Ischemic stroke  
Systemic embolism  
Thromboembolic events  
Cardiovascular outcomes  
Cardiac surgery  
Coronary artery bypass grafting (CABG)  
Valvular heart surgery  
Cardiac rhythm management device  
Pacemaker  
Implanted device  
CHADS2‑VASc score  
Stroke risk  
Early postoperative atrial fibrillation  
Mortality

Page 127 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Intracerebral hemorrhage  
- Intracranial hemorrhage  
- Mechanical heart valve  
- Reversal agents  
- Andexanet alfa  
- Prothrombin complex concentrate  
- Factor Xa inhibitors  
- Warfarin  
- Vitamin K antagonists  
- Direct oral anticoagulants  
- Rivaroxaban  
- Dabigatran  
- Apixaban  
- Oral anticoagulants  
- Anticoagulation‑related bleeding  
- Anticoagulation reversal  
- Antithrombotic therapy  
- Stroke prevention  
- Left atrial appendage  
- Left atrial appendage closure  
- Watchman device  
- Percutaneous left atrial appendage closure  
- Epicardial left atrial appendage clipping  
- Surgical left atrial appendage obliteration  
- Antithrombotic prophylaxis  
- Bleeding risk assessment  
- Thromboembolic complications  
- Mechanical heart valve prosthesis  
- Valve replacement  
- St Jude Medical prosthesis  
- Activated charcoal  
- Hemodialysis  
- Gastrointestinal bleeding  
- Reinitiation of anticoagulation after bleeding  
- Anticoagulation bridging  
- Periprocedural management  
- Long‑term clinical outcome of antithrombotic therapy  
- Risk modelling  
- Stroke survivors  
- Hematoma expansion  
- Hematoma volume  
- Anticoagulant‑associated intracerebral hemorrhage  
- Anticoagulant‑related intracerebral hemorrhage  
- Intracranial hemorrhage survivors  
- Thromboembolism  
- Mortality  
- Recurrent stroke  
- Recurrent hemorrhage  
- Left atrial appendage thrombus  
- Cardiac surgical patients with atrial fibrillation  
- Robotics‑assisted epicardial left atrial appendage exclusion  
- Anticoagulant‑related intracranial haemorrhage surveillance  
- Anticoagulant reversal agents effectiveness  
- Bleeding risk assessment scores  
- Antithrombotic therapy in valvular heart disease  
- Antithrombotic therapy in native and prosthetic valves.

Page 128 Extracted Terms:
**Key terms related to heart disease**

1. Atrial fibrillation  
2. Anticoagulation  
3. Direct oral anticoagulants (DOACs)  
4. Vitamin K antagonists  
5. Warfarin  
6. Dabigatran  
7. Rivaroxaban  
8. Apixaban  
9. Edoxaban  
10. Heparin  
11. Low‑molecular‑weight heparin  
12. Bridging therapy  
13. Periprocedural management  
14. Perioperative management  
15. Implantable cardioverter‑defibrillator (ICD)  
16. Pacemaker  
17. Cardiac device implantation  
18. Acute coronary syndrome (ACS)  
19. Percutaneous coronary intervention (PCI)  
20. Coronary stenting  
21. Coronary artery disease (CAD)  
22. Stable coronary disease  
23. Valvular heart disease  
24. Peripheral artery disease (PAD)  
25. Chronic kidney disease (CKD)  
26. Heart failure  
27. Antithrombotic therapy  
28. Dual antithrombotic therapy  
29. Triple therapy  
30. Antiplatelet therapy  
31. Aspirin  
32. Clopidogrel  
33. Bleeding risk  
34. Thromboembolic risk  
35. Stroke prevention  
36. Systemic embolic events

Page 129 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Chronic atrial fibrillation  
- Non‑valvular atrial fibrillation  
- Valvular atrial fibrillation  
- Rheumatic heart disease‑associated atrial fibrillation  
- Mechanical heart valves  
- Mitral stenosis  
- Left atrial appendage occlusion  
- Heart failure  
- Pulmonary hypertension  
- Left ventricular thrombus  
- Stroke  
- Stroke risk  
- Bleeding risk  
- Anticoagulation therapy  
- Oral anticoagulants  
- Vitamin K antagonists (e.g., warfarin, phenprocoumon)  
- New oral anticoagulants (DOACs)  
- Dabigatran  
- Rivaroxaban  
- Apixaban  
- Edoxaban  
- Valve replacement (mechanical On‑X aortic valve)

Page 130 Extracted Terms:
**Key heart‑disease terms extracted from the text**

- Atrial fibrillation  
- Atrial flutter  
- Atrial arrhythmias  
- Stroke  
- Systemic embolism  
- Thromboembolic risk  
- Anticoagulation therapy  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoablation  
- Left atrial appendage  
- Left atrial appendage stunning  
- Left atrial size  
- Left atrial functional recovery  
- Cardiac rhythm control  
- Cardiac rate control  
- Ventricular rate  
- Heart rate  
- Beta‑blockers  
- Calcium‑channel blockers  
- Digoxin  
- Electrical cardioversion  
- Drug therapy (for arrhythmia)  
- Rhythm control strategies  
- Rate control strategies  
- Tachycardia  
- Brady‑tachycardia  
- Heart failure  
- Reduced ejection fraction (HFrEF)  
- Preserved ejection fraction (HFpEF)  
- Sudden death  
- Tachycardia‑induced cardiomyopathy  
- Implantable cardioverter‑defibrillator (ICD)  
- Cardiac resynchronization therapy (CRT)  
- Sick sinus syndrome  
- Pacing‑related atrioventricular dysfunction  
- HATCH score  
- PACE score  
- Oral anticoagulant discontinuation  
- Stroke risk stratification  
- Quality of life in atrial fibrillation  
- Cardioversion‑induced left atrial stunning  

These terms represent the core concepts related to heart disease highlighted throughout the referenced guidelines and studies.

Page 131 Extracted Terms:
**Key Terms Related to Heart Disease**

- Atrial Fibrillation  
- Atrial Flutter  
- Acute Rate Control  
- Long‑Term Rate Control  
- Intravenous Esmolol  
- Intravenous Verapamil  
- Intravenous Diltiazem  
- Metoprolol  
- Digoxin  
- Intravenous Amiodarone  
- Intravenous Magnesium Sulfate  
- Calcium Channel Blockers  
- Beta‑Blockers  
- Heart Failure  
- Reduced Ejection Fraction (HFrEF)  
- Congestive Heart Failure (CHF)  
- Ventricular Arrhythmias (tachyarrhythmias)  
- Cardiac Pacing  
- Pacemaker  
- Atrioventricular (AV) Node Ablation (AVNA)  
- Atrio‑Ventricular Junction Ablation  
- His‑Bundle Pacing  
- Dronedarone  
- Diltiazem Post‑Infarction Therapy  
- Digitalis Therapy (Digoxin)  
- Serum Digoxin Concentration  
- Cardiac Conduction  
- Cardiac Refractoriness  
- Ventricular Rate  
- Sudden Cardiac Death  
- Coronary Artery Disease (implicit in myocardial infarction context)  
- Myocardial Infarction  
- Atrial Tachyarrhythmias  
- Pacing Method (e.g., VVIR, cardiac resynchronization therapy)  
- Electrophysiology (catheter ablation, radiofrequency)  

These terms capture the core concepts and therapies discussed in the guideline excerpt.

Page 132 Extracted Terms:
- Atrial fibrillation  
- Heart failure  
- Congestive heart failure  
- Tachycardia  
- Tachycardiomyopathy  
- Cardiomyopathy  
- Atrial‑fibrillation‑related cardiomyopathy  
- Left ventricular ejection fraction  
- Right ventricular pacing  
- Left ventricular pacing  
- Ventricular remodeling  
- Ventricular dysfunction  
- Systolic dysfunction  
- Diastolic dysfunction  
- Atrioventricular nodal ablation  
- Atrioventricular junction ablation  
- Atrioventricular junctional radiofrequency ablation  
- Conduction system pacing  
- His bundle pacing  
- Left bundle branch area pacing leads  
- Physiologic pacing  
- Dual‑chamber pacing  
- Catheter ablation  
- Radiofrequency catheter ablation  
- Direct‑current ablation  
- Cryoablation  
- Anti‑arrhythmic drug therapy  
- Anti‑arrhythmic drug therapy for rhythm control  
- Rate‑control drugs  
- Rhythm‑control drugs  
- Pacemaker implantation  
- Cardiac electronic device implantation  
- Atrial fibrillation management strategies  
- Rhythm‑control strategy  
- Rate‑control strategy  
- Atrial fibrillation progression  
- Atrial fibrillation in patients with permanent pacemakers  
- Atrial fibrillation in patients with implanted devices  
- Atrial fibrillation and weight management  
- Atrial fibrillation and quality of life  
- Atrial fibrillation and ventricular fibrosis  
- Cardiac catheter ablation for atrial fibrillation with heart failure  
- ACC/AHA/HRS guideline on bradycardia and conduction delay  
- ACC/AHA guideline on atrial fibrillation  
- ESC guideline on atrial fibrillation  
- EAST‑AFNET 4 trial  
- CABANA trial  
- AATAC multicentre randomized trial  
- Atrial Fibrillation Follow‑up Investigation of Rhythm Management (AFFIRM) study  
- Atrial Fibrillation Treatment Trial (AFTR) – (e.g., Ablate and Pace trial)  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Long‑standing persistent atrial fibrillation  
- Atrial rate control  
- Atrioventricular junction ablation and pacing therapy  
- Physiologic pacing versus right ventricular pacing evaluation  
- Left ventricular–based cardiac stimulation post‑AV nodal ablation  
- Left bundle branch block management  
- AV nodal ablation strategies  
- Catheter ablation for atrial fibrillation in heart failure  
- Catheter ablation for atrial fibrillation in asymptomatic patients  
- Catheter ablation for atrial fibrillation in symptomatic patients  
- Ablation versus amiodarone for persistent atrial fibrillation in heart failure  
- Ablation versus drug therapy for atrial fibrillation in heart failure  
- Cardiac rhythm disorder registries (e.g., RecordAF, CAMERA MRI, Chinese Atrial Fibrillation Registry)  
- Early rhythm‑control therapy in atrial fibrillation  
- Long‑term effect of goal‑directed weight management in atrial fibrillation  

*(All terms are derived from the clinical statements, guideline titles, study names, and medical concepts mentioned in the provided text.)*

Page 133 Extracted Terms:
- Atrial fibrillation (AF)  
- Atrial flutter  
- Heart failure (HF)  
- Congestive heart failure  
- Heart failure with reduced ejection fraction (HFrEF)  
- Thromboembolism  
- Stroke  
- Stroke prevention  
- Cardioversion (electrical, pharmacologic, direct‑current)  
- Catheter ablation (radiofrequency, cryoballoon, surgical)  
- Rhythm control  
- Rate control  
- Transesophageal echocardiography (TEE)  
- Left atrial appendage (LAA)  
- Left atrial mechanical function  
- Atrial stunning  
- Pulmonary vein isolation  
- Mitral regurgitation (MR)  
- Tricuspid regurgitation (TR)  
- Valvular regurgitation  
- Atrial remodeling (electrical and structural)  
- Right‑sided heart remodeling  
- Anticoagulation (including DOACs such as rivaroxaban)

Page 134 Extracted Terms:
- Atrial fibrillation  
- Stroke  
- Thromboembolic events  
- Left atrial appendage  
- Device‑related thrombosis  
- Percutaneous left atrial appendage closure  
- Watchman device  
- EWOLUTION trial  
- PROTECT‑AF trial  
- Transesophageal echocardiography (TEE)  
- Cardiac computed tomography (CT)  
- Electrical cardioversion  
- Direct current cardioversion  
- Anticoagulation therapy  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Antiplatelet therapy  
- Heparin  
- Enoxaparin  
- Electrical remodeling  
- Left atrial blood flow characteristics  
- Stroke risk scoring (CHADS2/CHA₂DS₂‑VASc)  
- Peri‑device leak  
- FINCV study  
- RHYTHM‑AF study  
- Cardioversion‑BMI trial  
- Electrophysiology procedures  
- Cardiac arrhythmias  
- Electromechanical atrial function


Page 135 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Paroxysmal atrial fibrillation  
- Atrial tachyarrhythmias  
- Ventricular fibrillation  
- Cardio‑conversion (electrical cardioversion)  
- Pharmacological cardioversion  
- Ibutilide  
- Amiodarone  
- Propafenone  
- Flecainide  
- Procainamide  
- Dofetilide  
- Sotalol  
- Digoxin  
- Class Ic antiarrhythmic drugs  
- “Pill‑in‑the‑pocket” approach  
- Biphasic cardioversion  
- Synchronized cardioversion  
- Electrical direct‑current cardioversion  
- Intravenous anti‑arrhythmic therapy  
- Intravenous amiodarone  
- Intravenous propafenone  
- Intravenous flecainide  
- Intravenous ibutilide  
- Intravenous procainamide  
- Oral loading dose (propafenone, flecainide)  
- Cardiac rhythm disorders  
- Heart failure  
- Reduced left‑ventricular function  
- Systemic hypertension (as a risk factor for AF)  
- Pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White)  
- Sync failure / Iatrogenic ventricular fibrillation (complications of cardioversion)  
- Arrhythmic complications  
- Anti‑arrhythmic drug safety and risk/benefit analysis  
- Electrophysiological determinants of conversion efficacy  
- Symptomatic Atrial Fibrillation (study)  
- Coronary circulation (implied by cardiac rhythm management studies)

Page 136 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Sinus rhythm  
- Antiarrhythmic agents  
- Amiodarone  
- Sotalol  
- Ibutilide (class III agent)  
- Propafenone  
- Flecainide  
- Dronedarone  
- Dofetilide  
- Encainide  
- Moricizine  
- Magnesium sulfate (intravenous)  
- QT interval  
- Left ventricular function  
- Heart failure  
- Myocardial infarction  
- Cardiac arrest  
- Implantable defibrillator  
- Cardioversion (direct‑current and pharmacologic)  
- Proarrhythmic events  
- Arrhythmia suppression trials (e.g., CATCH, CASH, AFFIRM)  
- Class I antiarrhythmic drugs  
- Class III antiarrhythmic drugs  
- Oral dofetilide safety  
- Pill‑in‑the‑pocket therapy  
- Intravenous loading of sotalol  
- Symptomatic recurrence of atrial fibrillation  
- Maintenance of sinus rhythm  
- Ventricular arrhythmias related to antiarrhythmic therapy  

Page 137 Extracted Terms:
**Key terms related to heart disease found in the text**

- Atrial fibrillation  
- Atrial flutter  
- Congestive heart failure  
- Left ventricular dysfunction  
- Myocardial infarction  
- Ventricular tachycardia  
- Coronary artery disease  
- Torsade de pointes  
- Long QT syndrome  
- Drug‑induced arrhythmias  
- Antiarrhythmic drugs  
- Dofetilide  
- Sotalol  
- Amiodarone  
- Ibutilide  
- Procainamide  
- Dronedarone  
- Quinidine  
- Clarithromycin  
- Hypokalaemia  
- Syncope  
- Pulmonary toxicity  
- Thyroid dysfunction (amiodarone‑induced)  
- Hepatotoxicity (amiodarone‑associated)  
- Optic neuropathy (amiodarone‑associated)  
- Proarrhythmic effects  
- Intravenous ibutilide therapy  
- Pill‑in‑the‑pocket strategy  
- Intravenous sotalol therapy  
- Cardiac surgery (post‑operative arrhythmia conversion)  
- Antiarrhythmic drug follow‑up  
- C‑reactive protein  
- Glucocorticoid therapy (upstream therapy)  
- Upstream therapy (e.g., anti‑inflammatory approach)  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  

These terms capture the main concepts, conditions, drugs, and therapeutic strategies related to heart disease discussed in the excerpt.

Page 138 Extracted Terms:
- Atrial fibrillation  
- Heart failure  
- Renin‑angiotensin system inhibition  
- Angiotensin‑converting enzyme inhibitor  
- Angiotensin receptor blocker  
- Candesartan  
- Losartan  
- Valsartan  
- Irbesartan  
- Eplerenone  
- Aldosterone pathway blockade  
- Sodium‑glucose co‑transport‑2 (SGLT2) inhibitors  
- Omega‑3 fatty acids  
- Statins  
- Vitamin C  
- Radiofrequency catheter ablation  
- Cryoballoon ablation  
- Pulmonary vein isolation  
- Catheter ablation  
- Antiarrhythmic drug therapy  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Recurrent atrial fibrillation  
- Stroke  
- Cardiac arrest  
- Bleeding  
- Mortality  
- Left ventricular systolic dysfunction  
- Left ventricular hypertrophy  
- Advanced heart failure  
- Diabetes mellitus type 2  
- Perioperative atrial fibrillation  
- Postoperative atrial fibrillation  
- Electrocardiographic left ventricular hypertrophy  
- Cardiac surgery  
- Cardiovascular outcomes (e.g., major adverse cardiovascular events)

Page 139 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Supraventricular tachycardia  
- Pulmonary vein isolation  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoballoon ablation  
- Cryoablation  
- Left atrial appendage  
- Left atrial size  
- Left ventricular end‑systolic dimension  
- Heart failure  
- Heart failure with reduced ejection fraction  
- Stroke  
- Bleeding  
- Cardiac arrest  
- Rhythm control  
- Antiarrhythmic drug therapy  
- Arrhythmia progression  
- Ablation vs drug therapy  
- Cost‑effectiveness  
- Cost‑utility  
- Quality of life  
- Heart rate  
- Device‑detected subclinical atrial fibrillation  
- Atrial remodeling  
- Cavotricuspid isthmus ablation  
- Atrial tachycardia  
- Vascular risk factors  
- Atrial fibrillation progression  
- Atrial fibrillation management guidelines (AHA/ACC/HRS)  
- Atrial fibrillation clinical outcomes  
- Atrial fibrillation economic evaluation  
- Symptomatic vs asymptomatic atrial fibrillation  
- Atrial fibrillation in pediatric and young adult populations  
- Atrial fibrillation in patients ≤30 years  
- Atrial fibrillation in heart failure patients  
- Atrial fibrillation and stroke risk  
- Atrial fibrillation and mortality  
- Atrial fibrillation therapy outcomes  
- Atrial fibrillation treatment strategy  



Page 140 Extracted Terms:
- Atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Nonparoxysmal atrial fibrillation  
- Left atrial volume  
- Ventricular fibrosis  
- Cardiac magnetic resonance imaging (MRI)  
- Delayed enhancement MRI  
- T1‑mapping  
- Catheter ablation  
- Radiofrequency ablation  
- Pulmonary vein isolation  
- Superior vena cava isolation  
- Autonomic denervation  
- Rotor or rotor‑modulation ablation (FIRM, CONFIRM, FIRMAP)  
- Focal impulse modulation  
- Ablation index–guided ablation  
- Ablation of ectopy‑triggering ganglionated plexuses  
- Left atrial appendage isolation  
- Electrophysiological inducibility testing (burst pacing, adenosine challenge)  
- Dormant conduction  
- Stiff left atrial syndrome  
- Stroke risk in atrial fibrillation  
- Heart failure (congestive heart failure)  
- Antiarrhythmic drugs (e.g., amiodarone, cardioversion drugs)  
- Rhythm‑control therapy  
- Rhythm‑restoration outcomes  
- Sinus rhythm restoration  
- Arrhythmia‑free outcome  
- Stroke prevention in atrial fibrillation  
- Supraventricular tachycardia  
- Clinical guideline terminology (ACC/AHA/HRS, HRS/EHRA/ECAS)

Page 141 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Radiofrequency ablation  
- Cryoballoon ablation  
- Pulmonary vein isolation  
- Electrical posterior box isolation  
- Atrioventricular conduction  
- Atrial scar  
- Left atrial scar  
- Atrial high‑rate episodes  
- Recurrent atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Persistent atrial fibrillation  
- Atrioventricular nodal ablation  
- Antiarrhythmic drugs  
- Dronedarone  
- Amiodarone  
- beta‑blockers  
- Novel oral anticoagulants  
- Vitamin K antagonists  
- Apixaban  
- Warfarin  
- Dabigatran  
- Edoxaban  
- Rivaroxaban  
- Periprocedural anticoagulation  
- Minimally interrupted anticoagulation  
- Uninterrupted anticoagulation  
- Silent thromboembolic lesion  
- Periprocedural cerebral thromboembolism  
- Stroke  
- Major bleeding  
- Minor bleeding  
- Cardiac arrest  
- Mortality  
- Shortness of breath  
- Stiff left atrium  
- Esophageal lesion  
- Atri‑esophageal fistula  
- Pulmonary vein stenosis  
- Quality of life  
- Long‑term outcomes  
- Meta‑analysis  
- Randomized controlled trial  
- Prospective multicenter study  
- Propensity‑matched analysis  
- Swedish health registries  
- Clinical guidelines for atrial fibrillation  
- Ablation complication  
- Reintervention  
- Rehospitalization  
- Re‑ablation  
- Cryoablation  
- Radiofrequency irrigation  
- Ablation efficacy  
- Ablation safety  
- Ablation outcomes  
- Ablation vs antiarrhythmic drug therapy  
- Stroke prevention in AF  
- Ablation success rate  
- AF recurrence prediction  
- AF burden  
- AF management  
- AF‑related morbidity  
- AF‑related mortality  



Page 142 Extracted Terms:
- Atrial fibrillation  
- Atrial tachyarrhythmias  
- Atrial flutter  
- Catheter ablation  
- Radiofrequency ablation  
- Surgical ablation  
- Anticoagulation therapy  
- Oral anticoagulation  
- Thromboembolism  
- Bleeding risk  
- Left atrial appendage closure  
- Pacemaker  
- Implantable cardioverter‑defibrillator (ICD)  
- Ventricular pacing  
- Dual‑chamber pacing  
- Single‑chamber pacing  
- Atrial overdrive pacing  
- Antitachycardia pacing  
- Adaptive cardiac resynchronization therapy (Adaptive CRT)  
- Cardiac resynchronization therapy (CRT)  
- Heart failure  
- Sick sinus syndrome  
- Sinus node dysfunction  
- Bradycardia  
- Ventricular pacing burden  
- Pacing burden  
- Atrial fibrillation burden  
- Prolonged AV conduction  
- High‑grade atrioventricular block  
- His bundle pacing  
- Left bundle branch area pacing  
- Right ventricular pacing  
- Progression of atrial fibrillation  
- New‑onset atrial fibrillation  
- Persistent atrial fibrillation  
- Paroxysmal atrial fibrillation  
- Electrocardiogram (ECG)  
- QRS duration  
- Pacing algorithm  
- Cardioembolic risk  
- Stroke  
- Cardioversion  
- Atrial fibrillation prevention  
- Atrial fibrillation management  
- Cardioverter‑defibrillator therapy  
- Cardiac implantable electronic devices

Page 143 Extracted Terms:
- Atrial fibrillation  
- Catheter ablation  
- Surgical ablation (Cox‑Maze, hybrid convergence)  
- Heart failure (HF)  
- Congestive heart failure (CHF)  
- Left atrial remodeling  
- Left ventricular diastolic dysfunction  
- Left ventricular systolic dysfunction  
- Preserved ejection fraction (EF)  
- Reduced ejection fraction (EF)  
- Mid‑range ejection fraction  
- Rhythm control  
- Rate control  
- Anticoagulation  
- Novel oral anticoagulants (NOACs)  
- Amiodarone  
- Digoxin  
- Carvedilol  
- Bisoprolol  
- Diltiazem  
- Pacemaker (AV junction ablation, VVIR)  
- Implantable devices (including cardiac resynchronization)  
- Survival (long‑term, post‑ablation)  
- Mortality  
- Adverse outcomes (stroke, thromboembolism)  
- Clinical guidelines (2023 AF guideline, ESC Heart Failure registry)  
- CASTLE‑AF trial  
- CAMTAF trial  
- AATAC trial  
- AMICA trial  
- RAFT‑AF trial  
- CAMERA‑MRI study  
- CABANA trial  
- Catheter ablation‑vs‑medical‑therapy trials (e.g., MARQUO, MERCURY)  
- Coronary artery bypass grafting (CABG) with ablation  
- Mitral valve surgery with ablation  
- Hybrid and convergent ablation procedures  
- Ejection Fraction (EF) assessment  
- Echocardiographic diastolic parameters  
- Clinical outcomes in elderly populations  
- Cardiovascular Health Study variables  
- Atrial fibrillation burden  
- Patient‑reported quality of life (RATE‑AF trial)  

**(All terms extracted from the cited clinical statements and studies concerning heart disease.)**

Page 144 Extracted Terms:
- Atrial fibrillation  
- Atrial tachycardia  
- Atrial tachyarrhythmia  
- Atrial fibrillation ablation  
- Catheter ablation  
- Pulmonary vein isolation  
- AV nodal ablation  
- AV junction ablation  
- Cardiac resynchronization therapy (CRT)  
- Biventricular pacing  
- His bundle pacing  
- Left bundle branch area pacing  
- Conventional pacing  
- Right ventricular pacing  
- Conduction‑system pacing  
- Cardiac pacing  
- Rhythm control  
- Rate control  
- Strict rate control  
- Lenient rate control  
- Digoxin  
- Diltiazem  
- Amiodarone  
- Tachycardia‑induced cardiomyopathy  
- Idiopathic dilated cardiomyopathy  
- Dilated cardiomyopathy  
- Left ventricular systolic dysfunction  
- Reduced ejection fraction  
- Congestive heart failure  
- Heart failure  
- Ventricular arrhythmia  
- Ventricular tachycardia  
- Ventricular remodeling  
- Ventricular dyssynchrony  
- Sudden cardiac death  
- Ventricular rate  
- ICD (implantable cardioverter‑defibrillator) therapies  
- Ventricular pacing percentage  
- Cardiomyopathy  
- Antiarrhythmic therapy  
- Genetic testing for cardiomyopathy/arrhythmia genes  
- Titin loss‑of‑function variants  
- Cardiomyopathy genes  
- Arrhythmia genes  
- Physical activity  
- Obesity  
- Athletes (competitive athletes)  

These terms capture the principal heart‑disease concepts referenced throughout the provided text.

Page 145 Extracted Terms:
- Atrial fibrillation  
- Atrial fibrillation (athletes)  
- Atrial fibrillation (obesity)  
- Body mass index (BMI)  
- Direct oral anticoagulants (DOACs)  
- Warfarin  
- Apixaban  
- Rivaroxaban  
- Edoxaban  
- Anticoagulation in Class III obesity  
- Bariatric surgery pharmacokinetics of rivaroxaban  
- Valvular heart disease  
- Cerebrovascular events  
- Wolff‑Parkinson‑White (WPW) syndrome  
- Pre‑excitation syndromes  
- Supraventricular tachycardia  
- Accessory atrioventricular connections  
- Radiofrequency catheter ablation  
- Catheter ablation of accessory pathways  
- Procainamide  
- Quinidine sulfate  
- Ibutilide  
- Amiodarone  
- Diltiazem  
- Metoprolol  
- Digitalis  
- Verapamil  
- Flecainide  
- Propafenone  
- Hypertrophic cardiomyopathy (HCM)  
- Thromboembolism in HCM  
- Ischemic stroke in HCM  
- Stroke risk (atrial fibrillation)  
- Cardiac dysfunction (post‑exercise)  
- Inflammatory cytokines (exercise‑induced)  
- Intense endurance exercise  
- Epicardial adiposity  
- Abdominal adiposity  
- Cardiac imaging in structural heart disease  
- Clinical outcomes of atrial fibrillation  
- Predictors of cerebrovascular events in valvular heart disease  
- Population‑based study of WPW syndrome  
- Systematic review of atrial fibrillation in HCM  
- Meta‑analysis of obesity and atrial fibrillation  

These terms capture the key cardiovascular conditions, risk factors, therapies, and patient populations discussed in the guideline excerpts.

Page 146 Extracted Terms:
- Atrial fibrillation  
- Atrial arrhythmias  
- Supraventricular tachycardia  
- Hypertrophic cardiomyopathy  
- Congenital heart disease  
- Adult congenital heart disease (ACHD)  
- Heart failure  
- Catheter ablation  
- Pulmonary vein isolation  
- Antiarrhythmic drugs  
- Amiodarone  
- Flecainide  
- Encainide  
- Dronedarone  
- Dofetilide  
- Non‑vitamin K antagonist oral anticoagulants (NOACs)  
- Thromboprophylaxis  
- Oral anticoagulation  
- Pulmonary vein isolation (PVI)  
- Cryoballoon ablation  
- Rate control  
- Rhythm control  
- Postoperative atrial fibrillation (POAF)  
- Cardiac surgery  
- Coronary artery bypass grafting (CABG)  
- Valve replacement  
- Revascularization  
- Pericardiotomy  
- Posterior left pericardiotomy  
- Colchicine  
- Thromboembolic complications  
- Proarrhythmia  
- Amiodarone‑induced thyrotoxicosis  
- Amiodarone‑associated thyroid dysfunction  
- Body mass index (BMI) as a risk factor  
- Dronedarone therapy in severe heart failure  
- Preoperative β‑blockers  
- Postoperative β‑blocker use  
- Prevalence of atrial fibrillation  
- Mortality following ventricular arrhythmia suppression  
- Risk factors for arrhythmia in ACHD  
- Safety and outcomes of catheter ablation in ACHD  
- Efficacy of antiarrhythmic drugs in ACHD  
- Electro‑physiologic considerations in congenital heart disease  
- Specialized electrophysiologic care in ACHD  
- Atrial fibrillation ablation on uninterrupted oral anticoagulation  
- Cryoballoon ablation feasibility in ACHD  
- Heart rhythm management in ACHD  
- Thrombosis in congenital heart disease  
- Post‑pericardiotomy syndrome  
- Clinical outcomes after cardiac surgery  
- Post‑operative atrial fibrillation  
- Prevention of AF after cardiac surgery.

Page 147 Extracted Terms:
- Atrial fibrillation  
- Post‑operative atrial fibrillation  
- Post‑pericardiotomy syndrome  
- Colchicine (anti‑arrhythmic therapy)  
- β‑blockers (cardioselective and non‑selective)  
- Anticoagulation / anticoagulant therapy  
- Stroke (ischemic stroke, thromboembolic stroke)  
- Thromboembolic risk  
- Hyperthyroidism / thyrotoxicosis  
- Thyroid disease / thyroid hormones  
- Cardiovascular disease  
- Supraventricular tachyarrhythmias  
- Atrial flutter  
- Supraventricular arrhythmias in pulmonary hypertension  
- Pulmonary hypertension  
- Severe pulmonary arterial hypertension  
- Idiopathic pulmonary arterial hypertension  
- Sepsis‑associated atrial fibrillation  
- Critical‑care atrial fibrillation  
- Continuous rhythm monitoring (implantable cardiac monitor)  
- Electrocardiogram (ECG) monitoring  
- Catheter ablation of atrial flutter  
- Cardioversion (electrical)  
- Mortality (cardiac‑related)  
- In-hospital morbidity and outcomes  
- Arrhythmia recurrence  
- Antithrombotic therapy  
- Post‑operative cardiac complications  
- Congenital heart disease (implicit in arrhythmia research)

Page 148 Extracted Terms:
- Atrial fibrillation  
- Atrial flutter  
- Atrial arrhythmias  
- Supraventricular tachycardia  
- Pulmonary arterial hypertension  
- Pulmonary embolism  
- COPD (chronic obstructive pulmonary disease) – as a comorbidity affecting atrial fibrillation  
- Valvular heart disease  
- Mechanical heart valve  
- Cardiovascular disease  
- Congestive heart failure  
- Hypertension (pre‑existing and pregnancy‑related)  
- Cardio‑oncology  
- QT prolongation  
- Anti‑arrhythmic drugs (e.g., digoxin)  
- Oral anticoagulants (e.g., rivaroxaban, direct oral anticoagulants)  
- Vitamin K antagonists (e.g., warfarin)  
- Thromboembolism  
- Anticoagulation management during pregnancy  
- Anticancer therapies with cardiac toxicity (e.g., ibrutinib)  
- Cardiac arrhythmia risk factors in cancer  
- Atrial fibrillation incidence in major cancer subtypes  
- Atrial fibrillation mortality risk in cancer patients  
- Heart failure associated with new‑onset atrial fibrillation in cancer  
- Systemic blood pressure control (tight vs usual) in hypertensive patients  
- Sinus rhythm maintenance and targeted therapy in persistent atrial fibrillation  

(These terms represent key heart‑disease–related concepts extracted from the cited guidelines and studies.)

Page 149 Extracted Terms:
**Key heart‑disease terms extracted from the text**

1. Atrial fibrillation  
2. Stroke  
3. Systemic embolism  
4. Blood pressure control  
5. Brain natriuretic peptide (BNP)  
6. Post‑operative atrial fibrillation  
7. Thoracic surgery  
8. Allogeneic hematopoietic cell transplantation  
9. Pre‑transplant cardiac evaluation  
10. Ibrutinib‑associated atrial fibrillation  
11. Bruton tyrosine kinase inhibitors (BTK inhibitors)  
12. Chemotherapy‑induced arrhythmias  
13. Targeted therapy arrhythmias  
14. Cardio‑oncology arrhythmias  
15. Autonomic disorders  
16. Chronic kidney disease (CKD)  
17. End‑stage renal disease (ESRD)  
18. Liver disease (cirrhosis, hepatic impairment, non‑alcoholic fatty liver disease)  
19. Anticoagulation therapy  
20. Edoxaban  
21. Warfarin  
22. Non‑vitamin K antagonist oral anticoagulants (NOACs)  
23. Direct oral anticoagulants (DOACs)  
24. Vitamin K antagonists  
25. Intravenous/Oral Factor Xa inhibitors (e.g., rivaroxaban)  
26. Direct thrombin inhibitor (dabigatran)  
27. Direct oral anticoagulant pharmacokinetics  
28. Direct oral anticoagulant pharmacodynamics  
29. Catheter ablation for atrial fibrillation  
30. Pulmonary vein isolation  
31. Cerebral thromboembolism  
32. Silent cerebral embolism  
33. Electrocardiographic (ECG) monitoring  
34. Continuous rhythm assessment  
35. Insertable cardiac monitor  
36. Rhythm Evaluation for Anticoagulation With Continuous Monitoring (REACTCOM)  

These terms capture the primary cardiovascular concepts, conditions, therapies, and clinical investigation elements referenced in the provided guideline excerpt.

Page 150 Extracted Terms:
- Atrial Fibrillation  
- Cardiac Electrophysiology  
- Cardiac Pacing  
- Heart Rhythm  
- Cardiovascular Medicine  
- Heart and Vascular Institute  
- Cardiologist  
- Cardiac Electrophysiology Fellowship  
- Heart and Heart Rhythm Care  
- Cardiovascular and Metabolic Sciences  
- Myocardial  
- Cardiac  
- Heart  
- Framingham Heart Study  
- Heart Disease  
- Arrhythmia  
- Guideline  
- Diagnosis  
- Management

Page 151 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiac Electrophysiology  
- Cardiology  
- Cardiovascular Medicine  
- Cardiovascular Disease  
- Heart Rhythm  
- Heart diseases  
- Cardiac  

**Key medical‑device and pharmaceutical entities:**
- Abbott  
- Biosense Webster  
- Biotronik  
- Boston Scientific  
- Johnson & Johnson  
- Pfizer  
- Sanofi‑Aventis  
- Zoll  
- AstraZeneca  
- Bayer  
- Daiichi Sankyo  
- Roche

Page 152 Extracted Terms:
- Atrial Fibrillation  
- Cardiovascular Disease  
- Cardiology  
- Cardiovascular  
- Heart Failure  
- Advanced Heart Failure  
- Pulmonary Hypertension  
- Cardiac Electrophysiology  
- Cardiac Surgery  
- Heart Disease  
- Cardiovascular Disease Fellowship Program  
- Sarver Heart Center  
- Bluhm Cardiovascular Institute  
- Heart Center  
- Cardiac  
- Abbott  
- Atricure  
- Edwards Lifesciences  
- Medtronic  
- Johnson & Johnson  
- InCarda  
- Biotronik  
- EP Research Foundation

Page 153 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiac Electrophysiology  
- Heart Rhythm Disorders  
- Cardiac Pacing  
- Cardiovascular Disease  
- Cardiovascular Disease Prevention  
- Cardiac  
- Heart  
- Heart Rhythm  
- Electrocardiography  
- Rhythm  
- 2023 Guideline for the Diagnosis and Management of Atrial Fibrillation  
- Abbott  
- Medtronic  
- Boston Scientific  
- Biotronik  
- Biosense Webster  
- Atricure

Page 154 Extracted Terms:
- Atrial Fibrillation  
- Congenital Heart Disease  
- Cardiovascular  
- Cardiovascular & Metabolic Sciences  
- Heart Rhythm Society (HRS)  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- Pulmonary Hypertension (commonly associated with heart disease)  
- Heart Medicine/Heart Disease (general term)

Page 155 Extracted Terms:
- Atrial Fibrillation  
- Arrhythmia  
- Cardiology  
- Cardiovascular disease  
- Heart disease  
- Guideline (for the Diagnosis and Management of Atrial Fibrillation)  
- Circulation (journal)  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACCP (American College of Chest Physicians)  
- HRS (Heart Rhythm Society)

Page 156 Extracted Terms:
- Atrial Fibrillation  
- Heart Rhythm  
- Cardiovascular  
- Heart Disease  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- Heart Rhythm Society (HRS)  
- National Heart, Lung, and Blood Institute (NHLBI)  
- National Institutes of Health (NIH)  
- Diagnosis and Management of Atrial Fibrillation  
- Clinical Guidelines for Atrial Fibrillation  

